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ABSTRACT
Single-pass membrane receptor signaling plays vital roles in human
development and maintaining homeostasis. These membrane receptors can also
have causative functions in several diseases including cancer. Much is known
about the structure and signaling outcomes of these receptors but the
mechanistic details of how they pass an extracellular signal across the
membrane and into cytoplasm via the transmembrane (TM) domain is unclear. It
is further unknown how or if interactions with membrane lipids facilitate and/or
regulate these events. Here we use the TYPE7 peptide to target the TM region of
a receptor tyrosine kinase, EphA2. EphA2 engages in both tumorigenic (ligandindependent) and anti-tumorigenic (ligand-dependent) signaling making it an
attractive drug target. From TYPE7 we learned that the activity of EphA2 could
be modulated by interactions with a TM peptide. Findings from TYPE7 (Chapter
II), lead to hypotheses about the signaling states of EphA2 and interactions with
anionic lipids. We next demonstrated (Chapter III) that there is a TM
conformation-specific coupling of juxtamembrane residues of EphA2 with PIP 2
[phosphatidylinositol 4,5-bisphosphate]. Our data suggests that PIP2 promotes
dimerization of EphA2 in the ligand-independent state, potentially regulating
tumorigenic signaling. These findings add to the knowledge of the molecular
events of EphA2 signal transduction which is vital to designing effective
therapeutics. Finally, we investigated the effects that TM peptides can have on
their lipid environments. We developed (Chapter IV) a fluorescence recovery
after photobleaching (FRAP) protocol and an automated data analysis pipeline
using programs written in Python and Mathematica languages for the
determination of lipid diffusion coefficients. We used the pH responsive peptide
(pHLIP) as a model TM domain and FRAP in supported lipid bilayers to
investigate the effect of pHLIP on the rate of lipid diffusion.
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Chapter I. Introduction
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1.1 Membrane Proteins
Eukaryotic cells have lipid membranes to encapsulate their contents from the
extracellular environment and to generate intracellular organelles. Membranes
establish necessary boundaries so that the chemical processes that support life
can occur. While the encapsulation established by membranes is crucial, the flow
of information and certain molecules across this membrane is just as crucial. To
accomplish this, a host of membrane protein families have evolved. Peripheral
membrane proteins associate with one leaflet of the bilayer while integral
membrane proteins span both leaflets of the bilayer. Integral membrane proteins
account for roughly one third of the human proteome and can be categorized by
both structure and function (1). Membrane proteins can be grouped into several
broad, functional categories including transport proteins, enzymes, cell adhesion
proteins, and signaling receptors.
These proteins have different characteristics based on which membrane they
are localized to. While 22% of all human proteins exist at the cell surface they
represent 60% of all drug targets (2). Cell membrane receptors convey signals
from the outside of a cell to the inside of a cell. Structurally, they are comprised
of extracellular, transmembrane, and intracellular regions. The extracellular
domain(s) bind to a signaling molecule(s) (ligand) then confer that signal across
the membrane through the transmembrane region(s) to the intracellular
domain(s) resulting in downstream changes in intracellular signaling. Signaling
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molecules include hormones, neurotransmitters, growth factors, cytokines,
nutrients, and cell adhesion molecules (3).
The most abundant membrane receptors are G-protein coupled receptors
(GPCRs) (4) and single pass membrane receptors including the highly studied
receptor tyrosine kinases (RTKs) (the second largest family of membrane
receptors) (5). GPCRs have seven transmembrane domains (TMDs) and when
bound by an extracellular ligand pass the signal to a peripheral G-protein on the
membrane inner leaflet (6). The G-protein then affects downstream signaling
changes. A similar effect is achieved by RTKs which have a single TMD. Unlike
GPCRs, binding of an extracellular ligand results in the signal being transduced
to an intracellular kinase domain instead of a G-protein (7). Despite their
structural differences, both GPCRs and RTKs rely on their TMDs to confer
messages from outside of the cell to the inside of the cell.
1.2 Importance of transmembrane domains in signaling
Membrane spanning proteins can have α-helical or beta sheet secondary
structures. Due to their similar evolutionary origins to prokaryotes, beta barrel
proteins in eukaryotes are found almost exclusively in the mitochondria and
chloroplasts. Almost all plasma membrane proteins contain α-helical TMDs. In
order to confer information from the extracellular side of the membrane to the
intracellular side of the membrane TMDs must conduct some kind of dynamic
movement. Multi-pass receptors, like GPCRs, can undergo very large
rearrangements of subunits to achieve signal transductions. Single-pass
3

receptors on the other hand are limited to a handful of motions of their single
TMD while avoiding the high energetic cost of hydrophobic mismatch between
their non-polar amino acid side chains and the aqueous environment outside of
the bilayer. As described by Matthews et al. in their 2006 review, TMDs
participate in four motions: translation (lateral movements within the plane of the
bilayer), piston (vertical movements within the plane of the bilayer), pivot
(spinning around the peptide backbone axis) , and rotation (tilting within the plane
of the bilayer) (Figure 1) (8). Combining certain individual movements, TMDs can
engage in dynamic lateral interactions by forming dimers and higher order
oligomers. These interactions are medicated by very specific dimerization
interfaces (9, 10).
Two common TMD dimerization interface motifs are GASright (glycine, serine,
alanine, right-handed) and left-handed dimers (11, 12). One of the first
dimerization sequences to be described is the glycine zipper (GXXXG) which is
an example of a GASright. Glycine zippers are common and highly over
represented in RTK TMD sequences (13). Glycine zipper mediated dimers are
stabilized by van der Waals forces and non-canonical Cα-H hydrogen bonding.
They also exhibit relatively large interhelical crossing angles of around 40° (14–
16).
Left-handed dimers on the other hand exhibit smaller crossing angles of 1520° (11). These dimers are mediated by heptad repeat motifs which are
repeating units of seven amino acids in which the sequence contains the
4

Figure 1. Four principle TMD motions.
TMDs can move via translation (laterally in the plane of the bilayer, piston
(vertically), pivot (rotation around the peptide backbone) and/or rotation (tilting)
motions due to hydrophobic constraints.
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following pattern: H-P-P-H-C-P-C. Where, typically, H is a hydrophobic residue, P
is a polar residue and C is a charged residue (17). The interface tends to be
mediated by interactions between hydrophobic or charged residues (18).
The classic model of RTK activation involves a monomeric receptor
undergoing dimerization in a ligand dependent manner (19). However, in recent
years this model has been determined to be overly simplistic as it has been
found that many RTKs form unliganded dimers (20). Several studies have
suggested that receptors transition from one dimerization motif to another in a
manner that involves changes via pivoting and rotational movements of two
TMDs relative to each other. It has been proposed that this kind of change
occurs in fibroblast growth factor receptor (FGFR), Eph receptors, ErbB2/HER2,
and epidermal growth factor receptor (EGFR) (21–24). This can involve switching
from one right-handed interface to another in a different position on the helix as
seen in ErbB which switches from a C-terminal GXXXG motif to an N-terminal
GXXXG motif (24). Or, as is proposed, for EphA2 a switch from a right-handed
dimer to a left-handed dimer can occur (22). It has been shown that these
signaling related changes in dimerization also cause changes in localization at
the plasma membrane.
As will be discussed in detail below (section 1.6), the lipid environment in
which a TMD resides can have important functional consequences. Cell
membranes are organized laterally into distinct domains including lipid rafts.
Recent studies have shown that recruitment of membrane proteins into lipid rafts
6

is dependent on TMD structure and composition. It has been found that TMD
length, surface area and palmitoylation are strong predictors of raft affinity with
longer, palmitoylated TMDs with smaller surface areas preferring the raft
environment (25). This can have functionally important consequences for
signaling. For example, the urokinase-type plasminogen activator receptor
(uPAR/CD87) dimerizes and preferentially partitions with lipid rafts and this
partitioning accelerates downstream signaling outcomes (26).
1.3 pH Responsive Transmembrane Peptides
Due to their membrane-spanning ability and importance in conferring signals,
transmembrane domains have been highly studied for their potential as
therapeutic agents and targets. There exists a large group of membrane active
peptides which includes anti-microbial peptides, cell-penetrating peptides, and
pH responsive peptides. Perhaps the best known and well-characterized of this
last group is the pH low insertion peptide (pHLIP). The sequence of pHLIP is
from the C-helix of the bacteriorhodopsin protein from Halobacterium halobium
(27, 28). The unique sequence characteristics of pHLIP allow it to be soluble in
solution at neutral pH (state I), bind with lipids in solution at neutral pH (state II)
and form a transmembrane α-helix at acidic pH (state III) (Figure 2) (27, 28). This
behavior is due to the seven acidic amino acids in the sequence of pHLIP (Table
1). In their unprotonated state at neutral pH the peptide remains soluble and
unfolded. The peptide remains unstructured when it associates with lipid
membranes in
7

Figure 2. Three states of a pH responsive peptide.
pH responsive peptides are disordered and soluble in solution (State I) and will
bind with membranes (State II) at neutral pH. In a low pH environment, pH
responsive peptides form transmembrane α-helices (State III).
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state II. Upon a decrease in pH the acidic amino acids become protonated
driving α-helical formation and increased hydrophobicity resulting in state III (29,
30).
The characteristics of pHLIP are particularly appealing as an agent to target
solid tumors in cancer (31). The pH of the tumor environment in cancer is lower
than the rest of the body due to the Warburg effect (a shift toward anaerobic
glycolysis), which causes lactic acidosis, and poor blood perfusion in solid tumors
(32). The logic behind using pHLIP as a therapeutic agent is that it will bypass
cells at a healthy pH and selectively insert into only those in an acidic
environment. Studies have shown that pHLIP is, in fact, not toxic to healthy
tissues while inserting into cells at low pH (33). When injected into mouse cancer
models, pHLIP successfully accumulates in tumors regardless of tumor size (31).
The potential applications for pHLIP are numerous and are continually being
explored.
Early studies demonstrated that pHLIP could carry cytotoxic agents or other
membrane impermeable drugs across the plasma membrane and into cells (34–
36). pHLIP has also been used to deliver gold nanoparticles to tumors in mouse
models (37). More recently, pHLIP has been used to deliver gene silencing
siRNA into cancer cells and antisense RNAs which inhibit long non-coding RNAs
sensitizing tumors to other treatments (38, 39).
In addition to direct therapeutic applications, pHLIP has also been employed
for targeted imaging of tumors (40). When conjugated to a radionuclide, pHLIP
9

has been used in positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) to produce high contrast diagnostic
images (41–43). Fluorescently labeled pHLIP has been used to effectively target
and label several different types and sizes of tumors and malignant lesions (44–
46). These fluorescently labeled versions of pHLIP may be useful for precisely
labeling tumor margins enabling complete surgical excision.
Unsurprisingly, the advances made with pHLIP have spawned new pHresponsive peptides bearing high to low sequence similarity to pHLIP as
researchers seek to fine-tune the application of these peptides. Several pHLIP
variants have been generated by changing the one or both of the titratable
aspartic acids from the WT sequence resulting in variants with altered pK a values
(47). By contrast, our lab developed the acidity-triggered rational membrane
(ATRAM) peptide which has less than 25% sequence identity to pHLIP but
engages in the same three-state insertion process as pHLIP. ATRAM however,
inserts into cells at a higher pH than pHLIP (6.5 vs. 5) which targets the mildly
acidic environment of cancer cells more efficiently (48).
Taking the departure from pHLIP even further, our lab has been testing the
ability to design pH-responsive peptides based on transmembrane domains of a
variety of membrane proteins. Current projects include peptides which target Tcell receptor (TCR) and neurotrophic tyrosine kinase, receptor-related 1 (ROR1).
We recently published the TYPE7 peptide which binds to the receptor tyrosine
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kinase EphA2 in cancer cells and modulates its signaling (49). Studies involving
TYPE7 are discussed in detail in Chapter 2.
1.4 Receptor Tyrosine Kinases
The largest family of enzyme-linked cell surface receptors are the receptor
tyrosine kinases (RTKs). RTKs are single-pass membrane proteins whose
activation by binding to an extracellular ligand induces phosphorylation events by
an intracellular kinase domain. Humans express 58 known RTKs which fall into
20 families. They are key regulators critical processes such as cell cycle,
metabolism, proliferation, differentiation, and migration (50, 51). All RTKs have
the same basic domain architecture: an extracellular, N-terminal ligand binding
domain, a single pass TMD, an intracellular juxtamembrane regulatory region, a
protein kinase domain, and a C-terminal regulatory region (7). RTKs engage in
lateral interactions in cell membranes forming dimers or larger order oligomers.
Dimerization or oligomerization may or may not precede binding of an
extracellular ligand. Nevertheless, ligand binding is believed to drive changes in
oligomerization via the extracellular domains which is conferred to the
intracellular domains to activate kinase activity resulting in cross-phosphorylation
of the RTKs. The phosphorylated protein then becomes a scaffold for assembly
and activation of downstream signaling effectors (50).
Ligands induce dimerization of the extracellular domains frequently in the
form of a divalent ligand that binds to two ligand binding domains of an RTK
forming a heterotetramer. This kind of organization has been identified in crystal
11

structures of several RTKs including vascular endothelial growth factor (VEGF)
receptor, Eph receptors, the nerve grown factor TrkA, and Tie2 (52–57). This
kind of complex can involve only receptor-ligand interactions, as in TrkA, or it can
involve dimerization interfaces between other regions of the extracellular
domains, as in KIT, FGRF and Eph receptors (56, 58–60).
Upon activation by ligand binding, crystal structures of the kinase domains of
all RTKs adopt a similar form (7). RTK kinase domains have an N-lobe and Clobe. The activation loop and the αC helix in the kinase N-lobe adopt a specific
configuration in all activated RTK kinase domains which is required for
phosphorylation to occur (61). On the other hand, structures of inactive kinase
domains vary, indicating diverse mechanisms of regulation (7).
Kinase domains can be autoinhibited by the activation loop, juxtamembrane
(JM) region, or C-terminal regions. Activation loops can inhibit kinase domains in
different ways. For example, in the insulin receptor there is a tyrosine residue in
the activation loop that projects into the active site thereby occluding the active
site. This configuration is stable and blocks access to ATP and protein substrates
(62). Upon ligand activation, a different tyrosine residue becomes transphosphorylated causing the activation loop to become “active” and released from
the autoinhibited state (61). Juxtamembrane autoinhibition involves the
unstructured JM making extensive stable contacts with the kinase domain
including the activation loop. These contacts involve tyrosine residues of the JM
which upon ligand stimulation, become phosphorylated releasing the
12

autoinhibited state (62). While the exact details of these interactions vary, this
kind of autoinhibition has been observed in KIT, Flt3, and Eph receptors (63–65).
Finally, an interesting mechanism of C-terminal mediated autoinhibition of the
kinase domain is exhibited by Tie2. A region in the C-terminal tail containing
phophorylatable tyrosines contacts the kinase domain and blocks substrate
access to the active site (66). These methods of self-regulation are believed to
prevent premature activation of the RTKs.
Upon ligand activation, RTKs undergo a series of trans and
autophosphorylation events. The result is the formation of downstream signaling
complexes. The first result is the recruitment of proteins containing SH2 or PTB
domains that bind to phosphotyrosines in the RTK (67, 68). These proteins
become phosphorylated and recruit other proteins to the RTK which become
phosphorylated as well. Some interact directly with the phosphotyrosines of the
RTK or indirectly through other docking proteins (69). With multiple
phosphotyrosines on each receptor and docking partners, RTKs are primed to
influence a wide variety of signaling pathways.
These signaling pathways were once thought to be linear but have since
been revealed to be branching, interconnected networks. The result is complex
and dynamic signaling with RTKs acting as nodes in the networks. Positive and
negative feedback loops are integrated across multiple members of a network to
effect different cellular outcomes. These networks are vast and complex. For
example, the signaling network of EGFR contains 211 reactions with 322
13

components (70). Also, simply knowing the components involved does not allow
for predicting cellular outcomes.
Recently, Zinkle and Mohammadi proposed a threshold model for RTK
signaling and cellular response (71). They suggest that quantitative differences in
the strength/longevity of ligand-activated dimers results in quantitative and
qualitative difference in activation loop tyrosine phosphorylation (how many vs.
the pattern of residues which get phosphorylated). The quantitative differences,
they claim, lead to differences in duration of signaling while the qualitative
differences lead to recruitment of distinct substrates and therefore activation of
distinct pathways. For example, studies with FGFR have revealed that some
phosphorylation sites are sensitive to dimer stability meaning that some sites
require different degrees of dimer stability in order to become phosphorylated
(72, 73). It has also been shown that specific adaptor proteins only bind to and
become activated by specific phosphorylated tyrosines in FRGR activation loop
(72). In this way FGFR can affect different cell outcomes (like cell migration vs
cell proliferation) which result from binding of different ligands which promote
dimers that have different stabilities. Data like this exists for many other receptors
supporting the threshold model for RTK pathway activation (71).
RTK signaling is typically downregulated by endocytosis and degradation of
the receptor. When internalized, RTKs continue to promote signaling until the
receptor is dephosphorylated, ubiquitylated, and finally the ligand is removed in
the acidic environment of the lysosome (7, 74, 75). The step of endocytosis at
14

which each of these occur depends in the RTK and ligand pair. Some RTKs are
degraded while some are recycled back to the cell surface. Ubiquitylation of
RTKs has been shown to be important in designating receptor fate. Several
studies show that mono-ubiquitylation directs RTKs to clathrin coated pits for
endocytosis and degradation (76). On the other hand, studies with EGFR have
shown that ubiquitylation is not necessary for endocytosis but only for
degradation (77, 78). The exact roles of mono- and polyubiquitylation in RTKs is
an ongoing area of research.
Beyond their signaling functions in healthy tissues, RTKs are of immense
interest due to their dysregulation and deregulation resulting in human diseases,
particularly cancers. RTKs promote cancer through 4 key mechanisms: autocrine
activation, chromosomal translocations, overexpression, and/or gain-of-function
mutations. The EGFR family of receptors is known to be overexpressed, often
due to gene duplication, in several cancers (79). The KIT family of RTKs
demonstrate activating gain-of-function mutation in gastrointestinal stromal
tumors, acute myeloid leukemia, mast cell leukemia, and melanoma (80–83).
Chromosomal translocations are responsible for expression of FGFR dimeric
fusion proteins which are constitutively active in several cancers (84).
1.5 Introduction to Eph receptors and EphA2
Of the RTKs, the largest family are the Eph receptors with 14 genes in the
human genome. Eph receptors are of interest as models for RTK structure and
function, their unique signaling modalities, and their roles in human diseases.
15

Eph receptors pair with ephrin ligands and are classified as EphA or EphB based
on the structure of their ephrin ligand. Type A ephrins are bound to the cell
membrane via a glycosylphosphatidylinositol (GPI) linkage while type B ephrins
are single-pass membrane proteins. In addition to the forward signaling induced
by kinase activation on the Eph receptor bearing cell, ligand binding results in
reverse signaling on the ephrin bearing cell. Type-A ephrins which lack
intracellular domains rely on co-receptors while type-B ephrins have SRC
homology 2 and PDZ binding motifs to interact with downstream signaling
components. In either case, ephrin reverse signaling affects cell retraction,
migration, adhesion, and proliferation. Ephrin reverse signaling has not been as
thoroughly studied as Eph forward signaling. Typically, Eph signaling performs
roles in tissue patterning during embryonic environment, wound healing, and
synaptic plasticity.
During embryogenesis, Eph receptors contribute to the formation of tissues
by regulating cell sorting. For example, Eph receptors help establish hindbrain
segmental patterning by preventing intermixing of cells from adjacent segments
(85, 86). Several Eph receptors play roles during angiogenesis. For example,
EphB4 is expressed in venous endothelial cells while ephrinB2, its ligand, is
expressed in arterial endothelial cells. Their interactions are believed to define
boundaries between endothelial venous and arterial cells (87, 88).
Typically, in healthy adult tissues, Eph expression becomes limited with some
exceptions. In the brain, EphA4 participates in synaptic plasticity. Among other
16

effects, EphA4 signaling in neurons leads to phosphorylation of the non-receptor
tyrosine kinase c-Abl1(89, 90). c-Abl is responsible for cytoskeletal remodeling
via actin depolymerization which causes growth cone collapse and the retraction
of dendritic spines known as dendrite pruning(91). Further, EphA4 activation
results in the removal of the synaptic glutamate AMPA receptor (AMPAR),
decreasing synaptic strength (92, 93). Removal of AMPAR and dendrite pruning
are part of healthy neuroplasticity and work to maintain appropriate excitatory
signaling strength.
Several Eph receptors and ephrins are involved in inflammation and wound
healing. For example, after lung injury is induced, EphA2 and ephrinA1 are both
upregulated (94, 95). It is believed that in the vascular endothelium
EphA1/ephrinA1 regulates secretion of pro-inflammatory signals such as
monocyte chemoattractant protein and C-X-C motif chemokine ligand 1. As
mentioned above, EphB4/ephrinB2 are important for angiogenesis during
embryonic development. EphrinB2 expression is also induced during hypoxia,
driving angiogenesis through induction of vascular endothelial growth factor
signaling (96, 97).
Beyond these roles in healthy tissues, Eph receptors are involved in
many human diseases. As mentioned above EphA4 signaling regulates synaptic
homeostasis. However, in the context of Alzheimer’s disease (AD), EphA4 is
bound by amyloid β and aberrantly activates signaling leading to loss of dendritic
spines and synaptic signaling and also phosphorylation of the non-receptor
17

tyrosine kinase c-Abl1(7, 8, 16). In fact, blocking EphA4 signaling in tissue
culture and in AD mouse models has been shown to ameliorate synaptic defects
(90, 98). Interestingly, phosphorylation of c-Abl has also been linked to
phosphorylation of Cdk5 which in turn phosphorylates tau contributing to
neurofibrillary tangles, a hallmark of AD (99, 100). EphA4 is also overexpressed
in amyotrophic lateral sclerosis (ALS) where it causes motor neuron
degeneration(101, 102). Eph receptors have also been implicated in skeletal
malformations. For example, loss of EphB2/B3 signaling is implicated in
craniofacial bone malformations that cause cleft palate (103).
Additionally, a large body of research exists establishing that many Eph
receptors are overexpressed in a variety of cancer types. Specifically, EphA2
overexpression at both the mRNA and protein level is found in breast, ovarian,
prostate, and pancreatic cancers (104–107). Furthermore, EphA2
overexpression is correlated with cancer severity. For example, one study of
esophageal cancers found that 50% of patient tumors had EphA2 overexpression
that correlated with rates of lymph node metastasis and low rates of survival
(108). EphA2 overexpression has also been linked to poor survival rates in
glioblastoma, cervical, ovarian, and renal cancers (109–112).
Aside from overexpression causing disease, EphA2 is also a known
receptor for several viruses. EphA2 is a crucial receptor for Kaposi’s sarcomaassociated herpesvirus (KSVH). KSHV is the cause of Kaposi’s sarcoma and at
least two B cell malignancies (113). In several cell lines, expression levels of
18

EphA2 correlates with increased viral entry and deletion of the gene in mice
abolishes infection (114). Similarly, EphA2 is also an epithelial receptor for
Epstein-Barr virus (EBV) (115, 116). EBV causes gastric carcinomas and B cell
lymphomas (117). It was found that EBV binds to the ligand binding and
fibronectin type III repeat domains of EphA2 and RNA knockdown of EphA2 in
cells prevents EBV infection (115). Binding of EBV may be highly specific to
EphA2 as it was found that EBV does not bind to the closely related EphA4
(116). EphA2, together with EGFR, has also been identified as a host cofactor for
Hepatitis C viral entry (118).
To better understand its role is disease, we must examine the function of
EphA2. EphA2 signaling pathways control cell proliferation, migration, and cell
retraction (119). It has been demonstrated in several studies that overexpression
of EphA2 in cancers is accompanied by a loss of ephrin ligand (120, 121). It is
believed that this imbalance of EphA2 overexpression and loss of liganddependent signaling causes tumor formation.
Eph2 and all Eph receptors share the same common RTK domain
architecture (Fig. 1) with a ligand binding domain (LBD), cysteine rich domain
(CRD), two fibronectin-like repeats (FN), a transmembrane domain (TMD), a
disordered juxtamembrane (JM) region, kinase domain (KD), sterile α motif
domain (SAM) and a PDZ-binding motif.
Ephrin binding induces formation of heterotetramers via ephrin-LBD and LBDLBD interactions. Eph-Eph dimerization is also facilitated by CRD-CRD
19

interactions (56). This results in the formation of large, micron sized, signaling
clusters at the plasma membrane (122, 123).
EphA2 is has two modes of signaling: ligand-independent and liganddependent. Ligand-independent (Figure 3, left) is responsible for tumorigenic
phenotypes via phosphorylation of S897 by AKT, RSK, and PKA (124–127).
EphA2 phospho-S897 is known to localize to the leading edges of migratory cells
where it is believed to promote assembly of the actin cytoskeleton in lamellipodia
extensions (124, 126). EphA2 phospho-S897 promotes RhoG/Rac activation
which promotes cell motility. EphA2 induced RhoG activation was also found to
inhibit apoptosis through PI3K interactions (128), and EphA2 serine
phosphorylation was found to prevent cell retraction (127).
Conversely, ligand-dependent signaling requires activation of EphA2 by its
ligand ephrinA1 (Figure 3, right). Ligand binding causes changes in dimerization
and the formation of large oligomers. The kinase domain is then activated
resulting in the phosphorylation of Y588, Y594 and Y772. Ligand-dependent
signaling has been shown to inhibit metastatic phenotypes by causing decreases
in proliferation, migration, and cell retraction/rounding (124, 129, 130). For
example, tyrosine phosphorylation inhibits mitogen-activated protein (MAP)
kinase phosphorylation which reduces cell proliferation(131, 132). Ephrin induced
phosphorylation recruits SHP-2 which dephosphorylates focal adhesion kinase
(FAK) which disrupts integrin function and results in decreased cell adhesion
(129). FAK is also believed to be responsible for the cytoskeletal rearrangements
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Figure 3. Architecture and oligomerization of EphA2 in two signaling
states.
(Left) In the ligand-independent state EphA2 exists in a monomer-dimer
equilibrium. Pro-tumorigenic signaling is promoted via phosphorylation of S897.
(Right) Upon binding of ephrinA1 on an adjacent cell, EphA2 forms large
signaling clusters and the kinase domain is activated resulting in transautophosphorylation of three tyrosine residues resulting in downstream antitumorigenic signaling.
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that cause ephrinA1-induced cell rounding/contraction (133). Finally, liganddependent signaling results in endocytosis of Eph signaling clusters. From the
endosome, the receptors are either degraded or recycled back to the plasma
membrane (134–136).
While many aspects of Eph receptor signaling have been worked out, the
exact molecular details of how the receptor passes an extracellular signal across
the plasma membrane are unknown. As a membrane spanning receptor, the
transmembrane domain (TMD), must play a role in conferring signals.
To investigate interactions between TMDs of EphA2, an NMR structure of the
TMD dimer was solved (137). To the authors’ surprise, it was found that this
dimer interface is mediated by a heptad repeat motif even though the EphA2
TMD sequence contains a glycine zipper (GXXXG) dimerization motif which is
generally overrepresented in RTK TMD dimer interfaces (13). In the same 2010
study, Bocharov et al. also conducted molecular dynamics (MD) on the NMR
structure and found upon relaxation that the EphA2 TMD dimer rotated to the
glycine zipper interface. It was then hypothesized that the receptor can switch
between these two dimerization interfaces.
In a follow-up study it was reported that mutations in the heptad repeat
decreased ligand independent signaling while mutations in the glycine zipper
decreased ligand-dependent signaling (22). These findings combined with the
structural data gave rise to the following model (Figure 4): In the ligand-
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Figure 4. Structures of EphA2 TMD dimers in two signaling states.
(Left) In the ligand-independent state the EphA2 TMD dimerizes via a heptad
repeat motif with a small interhelical crossing angle. (Right) Upon binding of
ephrinA1 the EphA2 TMD dimer rotates to a glycine zipper motif resulting in a
larger interhelical crossing angle. (Bottom) Sequence of EphA2 TMD
highlighting HR residues (fuchsia) and GZ residues (navy) as identified by
Bocharov et al., 2009.
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independent signaling state the EphA2 TMD dimerizes via the heptad repeat
(Fig. 2, left) with a helical crossing angle of 15° while in the ligand-dependent
(Fig. 2, right) signaling state EphA2 dimerizes via the glycine zipper with a helical
crossing angle of 45° (22, 137). It is unknown how the switch in dimerization
interface and opening of the interhelical crossing angle participates in conferring
the extracellular signal from the outside of the cell to the inside. It is also
unknown if the JM region responds to these changes in TMD orientation. It is
also unknown if or how the lipid environment interacts the TMD and JM of
EphA2. We investigate this in Chapter 3.
1.6 Phospholipids and functional roles in signaling
Plasma membranes of cells are composed of lipids, proteins, and
carbohydrates (138). Of these components, the lipids are grouped into three
major classes: phospholipids, cholesterol, and glycolipids (139). Phospholipids
make up the majority of the plasma membrane lipids. Phospholipid molecules are
composed each of a polar head group with two hydrophobic hydrocarbon tails of
varying degrees of saturation and length (139) and, in aqueous environments,
will spontaneously form bilayers by orienting their headgroups towards the
solvent and their acyl chains toward each other.
Phospholipids fall into two groups: glycerophospholipids (containing a
glycerol and phosphate headgroup) and phosphosphingolipids (containing a
sphingosine backbone and phosphocholine). Common examples of
glycerophospholipids found in membranes include phosphatidylcholine (PC),
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phosphatidylserine (PS), and phosphatidylethanolamine (PE) while
sphingomyelin (SM) is a common a phosphosphingolipid. Together these lipids
comprise most of the structure of the cell membrane. The plasma membrane has
a unique asymmetry with the outer leaflet being primarily PC and SM while the
inner leaflet being primarily PE, PS and phosphatidylinositol.
Of the phospholipids, phosphoinositides represent a small fraction of lipids
in the plasma membrane (140). Despite their low abundance they play vital roles
in crucial cellular processes. Phosphatidylinositol(4,5)-bisphosphate (PIP2) and
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) make up less than 1% of
membrane phospholipids but regulate important signaling pathways (140, 141).
As such, the relative levels of phosphoinositides are under careful regulatory
control. PIP2 is synthesized in two steps. First, phosphatidylinositol is converted
to Phosphatidylinositide(4)-phosphate (PI(4)P) by phosphatidylinositol 4-kinase
and then PI(4)P is converted to PIP2 by PI(4)P kinase 5α (142). PIP2 can then be
phosphorylated to generate PIP3 by phosphatidylinositol 3-kinase or
dephosphorylated by phospholipase C (PLC) to inositol triphosphate (IP3) and
diacylglycerol (DAG). IP3, DAG, and PIP3 are all important secondary
messengers.
When cleaved by PLC from PIP2, IP3 is released as a soluble molecule
which is then free to diffuse through the cell to the endoplasmic reticulum where
it binds to a ligand-gated calcium channel causing the release of intracellular
Ca2+ stores (143, 144). Meanwhile, DAG remains at the membrane where it
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binds to and activates protein kinase C (PKC) (144). PKC phosphorylates
proteins in a wide variety of signal transduction cascades depending on the
specific cell type (145, 146).
Phosphoinositides are bound by proteins containing pleckstrin homology
(PH), ezrin/radixin/moesin family (FERM), and epsin N-terminal homology
(ENTH) domains (147–149). Proteins with ENTH domains (epsin and CALM) are
believed to bind to PIP2 and regulate the assembly of clathrin coats at sites of
endocytosis (148, 150). Dephosphorylation of PIP2 by synaptojanin to PI(4)P
induces the disassembly of the clathrin lattice (151). ERM family proteins have
an N-terminal FERM domain that binds to the C-terminus of the protein. Upon
FERM binding to PIP2 the C-terminus is released, and the protein is able to
interact with other proteins involved in linking actin to the plasma membrane
(152). PH domains have been identified in over 100 proteins which play roles in
reorganization of the actin cytoskeleton. Most PH domains will bind any
phosphoinositide with high affinity and low selectivity (153). There are a handful
of exceptions to this observation which bind selectively to PIP2 or PIP3
exclusively underscoring the importance of these lipids.
In addition to these structured domains, there are several examples of
proteins with unstructured regions which bind to PIPs. A common feature to
these proteins is regions containing clusters of basic residues. For example,
MARCKS (Myristoylated Alanine-Rich C-Kinase Substrate) is an unstructured
protein with a myristate membrane anchor. The myristate alone however is not
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sufficient for tethering the protein to the membrane. MARCKS contains a region
of 13 basic residues which bind electrostatically to the negatively charged PIP 2
headgroup with high affinity helping to attach MARCKS to the membrane (154).
Binding of this region by Ca2+/calmodulin results in the release MARCKS from
the membrane into the cytosol (155). This mode of electrostatic binding to PIP2
has been demonstrated for other proteins/domains.
It has been proposed that electrostatic interactions with PIP2 of the JM
and kinase domains of EGFR are responsible for autoinhibition of the receptor
(156, 157). It has been shown that the JM and kinase domains, which have
positively charged residues interact with PIP2 containing membranes. During
ligand-induced activation of EGFR the receptor undergoes TMD dimer
rearrangements and trans-autophosphorylation occurs via the kinase domains.
These phosphorylation events result in the activation of downstream signaling
cascades. It is believed that electrostatic interactions with PIP2 of the JM and
kinase domains prior to ligand binding prevent inappropriate signaling events.
The transition of the JM and kinase domains from the membrane bound to
unbound state is facilitated by binding of Ca2+/calmodulin to basic JM residues
(156, 158). This binding is believed to outcompete the PIP2 interactions and
release both the JM and kinase domains thereby facilitating signaling (156, 157).
A key aspect of this model is the coupling between changes in TMD dimerization
and changes in JM-PIP2 interactions.
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A similar mechanism has been proposed for FGFR. In one study it was
observed that FGFR TMD tilt angle is coupled to JM-PIP2 interactions (21). The
authors proposed that the FGFR unliganded dimer exhibits more tilted TMDs and
that in this state the JM is tethered to the membrane via PIP 2 interactions while
the liganded dimer exhibits less tilted TMDs and in this state the JM is released
from the membrane (21). The importance of these electrostatic interactions
between juxtamembrane domains and PIP2 are currently being explored for other
receptors. For example, molecular dynamics simulations have been used to
predict strong interactions of PIP2 with all 58 RTKs and tropomyosin receptor
kinase A (TrkA) (159, 160). Specifically, strong interactions with the JM and
kinase domains of EphA2 have been predicted but have not been demonstrated
experimentally. The functional implications of these interactions have also not
been established. EphA2 JM-PIP2 interactions are explored in detail Chapter III.
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Chapter II.
Interactions between TYPE7 and EphA2 in cells and effects on
cell morphology
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2.1 Abstract
EphA2 is capable of pro-tumorigenic and anti-tumorigenic signaling based
on its activation state. When bound by its ephrin ligand the anti-tumorigenic
signaling is activated while in its unbound form, it promotes tumorigenic
signaling. In the context of cancer, overexpression of the receptor and cleavage
of the extracellular domain promote the ligand-independent signaling. We
recently developed the pH responsive TYPE7 transmembrane peptide which
targets the TM domain of EphA2. TYPE7 causes phosphorylation of a single
tyrosine residue and decreased migration of cancer cells, partially mimicking
ligand activation. Here we show that TYPE7 associates with endogenous EphA2
in cancer cells at the plasma membrane. We further explore cell contraction,
another outcome of ligand-dependent signaling, with TYPE7 and the natural
EphA2 ligand, ephrinA1 using both fixed and live cells.
2.2 Introduction
Eph receptors are receptor tyrosine kinases (RTKs) that comprise the
largest family of RTKs. Together with their ephrin ligands at cell-cell contacts,
Eph receptors are involved in tissue patterning during embryonic development,
neuronal plasticity, and wound healing (130). EphA2 signaling plays a role in
pathways which control cell proliferation, migration, and cell retraction (119). It is
also found to be over expressed in many cancers (130). Specifically, EphA2
overexpression is found among many others, in breast, ovarian, prostate, and
pancreatic cancers and is correlated with relatively aggressive tumors and poor
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patient prognosis (104–107). It is believed that EphA2 is involved in two methods
of signaling: ligand dependent and ligand independent. Ligand-independent
signaling is responsible for metastatic phenotypes via phosphorylation of S897
by AKT, RSK or PKA (125). Conversely, activation of EphA2 via its ligand
ephrinA1 and phosphorylation of tyrosine residues has been shown to inhibit
metastatic phenotypes (124). Specifically, EphA2 activation leads to decreases in
proliferation, migration, and cell retraction/rounding (130). For these reasons,
finding novel methods to activate EphA2 has become an attractive avenue of
investigation.
One logical means of promoting the anti-tumorigenic signaling would be to
treat tumors with EphA2 agonists. Efforts toward this have been made in the form
of antibodies and peptide drugs. As of August 2020, there are twelve antibody
drugs which target EphA2 in various stages of development (161). One
promising candidate is the mouse EA5 monoclonal antibody which binds to the
LBD of EphA2 and mimics the binding of an ephrin ligand. EA5 has been shown
to decrease tumor size and cell proliferation (162). Ephrin mimetic peptides like
the YSA peptide have also shown promise in targeting and activating liganddependent signaling of EphA2 (163).
However, in the tumor environment, the extracellular portion of EphA2 can
be cleaved by membrane type I-matrix metalloproteinase (MT1-MMP) thus
rendering the receptor blind to activation via the LBD (164, 165). The cleaved
receptor has been shown to promote tumorigenic signaling (165). It is therefore
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imperative to find a means to target and modulate EphA2 activity in a way that
does not depend on the ligand binding domain.
We have recently developed TYPE7 (transmembrane tyrosine kinase
peptide for Eph) to promote EphA2 activation by targeting the transmembrane
domain (49). TYPE7 was designed to block the transmembrane dimerization
interface that is involved in ligand-independent signaling. The occlusion of this
interface is believed to promote dimerization at the available ligand-dependent
interface. TYPE7 was also designed to be a soluble disordered coil at neutral pH
and from a transmembrane alpha helix at acidic pH. Lower than physiological pH
(6.5-6.9 vs. 7.2-7.4) is a hallmark of the tumor environment. By being responsive
to acidity, TYPE7 can, in theory, bypass healthy tissues and insert into the
membranes of cancer cells.
Biophysical experiments show that TYPE7 does form a transmembrane
alpha helix in the presence of liposomes at acidic pH. It was found that, in cancer
cells, TYPE7 inhibited cell migration as effectively as ephrinA1. Phosphorylation
studies demonstrated that this change in behavior was due to phosphorylation of
Y772 induced by TYPE7. With this data, we wondered if TYPE7 directly interacts
with EphA2 in cancer cells and if TYPE7 could affect other aspects of cancer cell
morphology and behavior. We further hypothesized that TYPE7 would have the
same effects on tyrosine phosphorylation and cell migration by interactions with
EphA2 lacking the extracellular domain.
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2.3 Methods
Cell Culture
PC-3 cells (ATCC, CRL-1435) in F-12K media (Gibco), A375 cells (ATCC,
CRL-1619), and Hek293 (ATCC, CRL-1573) were cultured in EMEM or DMEM
(Gibco) media. Media was enriched with 10% fetal bovine serum (Gibco), 5%
penicillin streptomycin (Gibco). Cells were cultured in a humidified incubator with
5% CO2.
Co-localization Analysis
A375 cells were plated at a seeding density of 1 x 104 cells per well in a
glass-bottom 8-well slide (Ibidi, Munich Germany) coated with 50 µg/mL rat tail
collagen I (Gibco, Waltham MA). 24 hours later cells were serum starved. 12
hours later the cells were pre-treated with DMEM containing 2 µM unlabeled
TYPE7 for 1 hour at 37° C to prevent high background seen in samples that were
not pre-treated. Samples were then treated +/- 0.5 µg/mL EphrinA1-Fc (R&D
Systems, Minneapolis MN) and +/- 0.2 µM of TYPE7-Alexa568 in PBS++ for 5
minutes at room temperature followed by a 2 minute wash with PBS++ then
immediately fixed in 4% PFA. Samples were then blocked for I hour at room
temperature in PBS with 5% goat serum (Gibco). Samples were then incubated
with 1:100 rabbit anti-human EphA2 mAb (Cell Signaling, Danvers MA) primary
antibody in PBS with 1% BSA (Fisher Scientific, Pittsburgh PA) for 1 hour at
room temperature. Samples were rinsed 3 time with PBS++ then incubated with
1:200 goat anti rabbit IgG Alexa488 antibody (Invitrogen) in PBS with 1%BSA in
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the dark at room temperature for 45 min. Samples were then rinsed 3 times with
PBS++, stained with DAPI and covered with VectaShield mounting medium for
fluorescence (Vector Laboratories, Burlingame CA).
Cells were imaged on a confocal laser scanning microscope (Zeiss LSM 710)
with 63x and 100x objectives and images were captured using Zen2 blue edition
software with excitation wavelengths of 504 nm, 488 nm, and 561 nm and
emission were collected at 410-481 nm, 496-584 nm, and 604-733 nm for Dapi,
Alexa488, and Alexa568 respectively. Co-localization were subsequently
quantified, and Pearson’s Correlation Coefficients were generated using the
ImageJ Co-localization Threshold plugin. Statistical analyses were performed in
IBM SPSS Statistics Software (version 24).
Cell Contraction in Fixed Cells
A375 or PC-3 cells were plated in 5 well of a 24-well plate on glass
coverslips at a seeding density of 1x105 cells per well. Cells were grown for 24
hours then, 2 wells were treated with 2 µM TYPE7 in serum free media. All other
wells were treated with serum free media. The next morning, cells were treated
with 0.5 µg/mL of Fc or EphrinA1-Fc and fresh 2 µM TYPE7 for 10 minutes at 37
°C. The treatments were combined to make the following groups: Control
(untreated), Fc only, Type7 only, ephrinA1-Fc only, and Type7 + ephrinA1-Fc.
After the 10-minute treatment, cells were rinsed with PBS++ and fixed with 4%
paraformaldehyde for 30 minutes at room temperature. Cells were then washed
3 times with PBS++ for 5 minutes each. Cells were then permeabilized with
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permeabilization buffer (0.3% Triton X-100, 0.1% bovine serum albumin (BSA) in
PBS) at room temperature for 15 minutes. Cells were then blocked in blocking
buffer (33% goat serum, 40 mM sodium phosphate, pH 7.4, 450 mM NaCl, 0.6%
Triton X-100) for 30 minutes at room temperature. Cells were then incubated with
1:100 rabbit anti-human EphA2 mAb primary antibody in blocking buffer for 1
hour at room temperature. Cells were then washed 3 times with permeabilization
buffer. Cells were then incubated with 1:200 goat anti rabbit IgG Alexa488
antibody and phalloidin CF594 (Biotium, Fremont, CA) in blocking buffer for 45
minutes at room temperature. Cells were then rinsed once with PBS++ and the
nuclei were stained for 3 min with Dapi. Coverslips were then rinsed with PBS++
then ddH2O and transferred to slides and mounted with VectaShield mounting
solution. Cells were imaged on a confocal laser scanning microscope (Zeiss
LSM 710) with 40x, 63x and 100x objectives and images were captured using
Zen2 blue edition software.
EphA2 immunostaining was used as a visual control to check that in cells
not treated with ephrinA1-Fc EphA2 is primarily localized to the plasma
membrane, Cells treated with ephrinA1-Fc were checked for EphA2 puncta and
endocytosis. Phalloidin staining of actin and Dapi stained nuclei were imaged for
measuring cytoplasmic area. To measure this, CellProfiler software (Broad
Institute) was employed (166). The “Human Cell” pipeline available online was
used for cell measurements. In this pipeline “primary objects” were set to nuclei
and identified in the blue channel while “secondary objects” were set to
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cytoplasm and identified in the red channel. For each, the global thresholding
strategy and Otsu thresholding method were selected for two-class thresholding.
To identify the cytoplasm, in “IdentifyTertiaryObjects” the larger identified object
was set to “Cells” and the smaller identified object was set to “Nuclei”. In
“MeasureObjectSizeShape”, “Cells”, “Cytoplasm”, and “Nuclei” were selected”.
From this pipeline several parameters are measured and exported including
area, eccentricity, form factor, maximum and mean radius. Due to large day to
day variability in cell areas, data were normalized to control (0% contraction) and
ephrinA1-Fc (100% contraction) treatments.
Live Cell Contraction
PC-3 cells were plated at a seeding density of 5000 cells per well and
grown for 24 hours. Cells were then serum starved overnight. The next day, cells
were placed in L-15 media for imaging. Cells were treated with 0.5 µg/mL
ephrinA1-Fc and were imaged via phase contrast every minute for 30 minutes.
Cell areas were measured by hand in ImageJ.
Truncated EphA2 Cloning
A pCMV6-AC-GFP EphA2 mammalian expression vector was purchased
(Origene, Cat. # RG205725). EphA2NT1296+AsiSIForward primer
(TATATAGCGATCGCATGAGCATCAACCAG) was designed to amplify from the
5’ end the EphA2 gene after nucleotide 1296 (S432), create point mutation
V433M, and add a AsiSI restriction sequence upstream on start codon.
EphA2+MluIReverse primer (TATACGCGTGATGGGGATCCC) was designed to
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amplify the 3’ end of EphA2 with a downstream MluI restriction sequence. The
primers were used to PCR amplify truncated EphA2 using the pCMV6EphA2GFP vector. The new PCR amplified gene insert and the template pCMV6-GFP
were restriction digested with AsiSI and MluI-HF and run on an agarose gel. The
resulting bands cut out and purified with gel clean-up kit. The digested insert and
vector were ligated with T4 DNA ligase using a 1:3 vector to insert ratio. The
sequence of the insert in the ligated vector was confirmed via Sanger
sequencing. The resulting vector was named EphA2ΔN-GFP.
Transfection and Western Blot Analysis
Hek293 cells were transfected with 1.5µg of DNA each of EphA2-GFP or
EphA2ΔN-GFP vectors using lipofectamine (Thermofisher, Waltham MA) in a 6well plate. 48 hours later, cells were imaged via fluorescence and brightfield
microscopy to check from GFP expression. For Western Blot, cells were lysed
with 50 mM Tris HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, and
protease inhibitors for 30 minutes on ice. The insoluble fraction was separated
via centrifugation at 10,000 x g for 30 minutes at 4°C. Lysate proteins were then
separated by SDS-PAGE on an 8% polyacrylamide gel and transferred to a 0.45
µm nitrocellulose membrane. Membranes were incubated with 1:1000 antiEphA2 rabbit primary antibodies or 1:10000 anti-β-actin mouse primary
antibodies. Membranes were subsequently incubated with 1:5000 anti-mouse
and anti-rabbit IR-dye conjugated secondary antibodies. Secondary antibodies
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were detected on an Odyssey Infrared Scanner (Li-Cor Biosciences, Lincoln,
NE).
2.4 Results
TYPE7 co-localizes with EphA2 in cells
To determine if TYPE7 co-localizes with EphA2 in cancer cells in culture,
we performed experiments by incubating Alexa568 labeled TYPE7 with A375
melanoma cells, fixing the cells, and performing immunohistochemistry to label
endogenous EphA2 with an Alexa488 antibody. By imaging with a scanning laser
confocal co-localization between TYPE7 and EphA2 could be visualized (Figure
5A). To quantify co-localization, the overlap in signals of Alexa568 and Alexa488
were determined in ImageJ and expressed as a Pearson’s correlation coefficient
(r) (Figure 5B). A positive correlation between exists between EphA2 and TYPE7
(r = 0.26, n =14) which increased significantly upon receptor activation with
ephrinA1-Fc (r = 0.38, n = 17) (p < 0.05). We calculated r for whole images to
reduce biases associated to selecting ROIs. We expect that correlation values
would be higher for just the plasma membranes of individual cells since a large
portion of EphA2 is internalized, whereas TYPE7 is not. These data were
validated by experiments showing that TYPE7 co-precipitates with EphA2 and
that the amount of TYPE7 co-precipitating with EphA2 increases significantly with
the addition of ephrinA1-Fc (49).
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Figure 5. TYPE 7 co-localizes with EphA2 in cancer cells.
A. Representative confocal images of A375 cancer cells treated ± TYPE7Alexa568 (red) and ± EphrinA1-Fc (EA1-Fc). Cells were fixed and
immunostained for EphA2 (green). B. Quantification of co-localization of red
and green dyes as seen in A via Pearson’s Correlation Coefficients. Bars are
means ± S.D., n = 3. *p < 0.05, from student’s t-test.
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Cell contraction studies in fixed cells
Since TYPE7 significantly reduced cell migration (49) we reasoned that
other EphA2 signaling-dependent changes in cell behavior and morphology may
be induced by TYPE7. Ligand-dependent activation of EphA2 results in dramatic
cell rounding and reduction of two-dimensional cell area. We sought to test if
TYPE7 also has a similar effect in cancer cells. To do this, we employed cell
contraction studies as described by Barquilla et al. (167). We initially conducted
these experiments in A375 melanoma cells to be consistent with the cell line
used in the cell migration assays. Cells were treated with TYPE7 and ephrinA1Fc, stained and imaged (Figure 6A). For these initial experiments, cells were
measured by hand in ImageJ (Figure 6B and C). These experiments and results
yielded significant differences between control and TYPE7 treated cell. However,
there were concerns about the relatively small number of cells measured and
bias introduced due to manual measurements. It was decided that a more highthroughput and unbiased method of measuring cell area would provide more
valid data.
We then implemented the open source software, CellProfiler, to measure
cell contraction in A375 cells. We also investigated another measure of cell
morphology, eccentricity, which is another output of the CellProfiler pipeline we
used. Eccentricity if a measure of how circular an object is. An eccentricity value
of 0 is a perfect circle where an eccentricity value of 1 is a parabola. We found
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Figure 6. Initial cell area measurements in A375 cells.
A. Representative confocal images of control, 0.5 µg/mL ephrinA1-Fc, and 2
µM TYPE7 treated A375 cells. Actin is label by phalloidin (red) and nuclei are
stained with Dapi (blue). B. Representative image showing manual
measurement of cell area as conducted in ImageJ. C. Average cell areas for
treated cells as measured manually in ImageJ. Bars are means ± S.D. * p <
0.05, as determined by ANOVA and Tukey post-hoc test, n = 3.
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Figure 7. Automated cell area and eccentricity of A375 cells.
A. Cytoplasmic area of treated A375 cells measure from confocal images using
CellProfiler. Bars are means ± S.D. B. Eccentricity of treated A375 cells as
measured in CellProfiler. Bars are means ± S.D.
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that there were no significant changes in cytoplasmic area (Figure 7A) or
eccentricity (Figure 7B) in A375 cells treated with ephrinA1 or TYPE7. We also
noticed that the relative change is area of A375 between control and ephrinA1-Fc
treatment was not as large as in published images of contracted PC-3 cells
(167).
Thus, we moved forward with conducting experiments in PC-3 cells
(Figure 8A) and measuring using the automated cell measuring software,
CellProfiler. With this new method, we found that ephrinA1-Fc did significantly
increase cell contraction (Figure 8B) in agreement with previously published data
(167). While it consistently appeared that TYPE7 induced cell contraction, the
change was never significant when compared to the Fc control. We believed this
was due to the high level of heterogeneity in cell sizes across the population.
Cell contraction studies in live cells
Studies in fixed cells gave results which had too high of a degree of
variability to determine any statistical significance. We also did not know if
maximal cell contraction was reached for most cells during the 10-minute
treatment prior to fixation. We reasoned that measuring cell contraction of
individual live cells might yield more reproducible results. Thus, we designed an
experimental set-up in which a small number of cells would be imaged (Figure
9A) before and during treatment so their size could be tracked over time. What
we found was that not all cells reached maximal contraction at the same time
post-treatment (Figure 9C). On a given day, cells might reach their maximal
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Figure 8. Cell contraction observed in PC3 cells.
A. Representative confocal images of PC-3 cells treated ± 0.5 µg/mL ephrinA1Fc (EA1-Fc) and ± 2 µM TYPE7. Actin is labeled with phalloidin (red) and nuclei
are stained with Dapi (blue). B. Normalized cell contraction quantified using
cytoplasmic areas from CellProfiler from confocal images. Bars are means ±
S.D. * p < 0.05, from ANOVA and Tukey post-hoc tests, n = 3.
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contracted size after 10 minutes (Figure 9C, orange line) of ephrinA1-Fc or 20
minutes (Figure 9C, blue line) of ephrinA1-Fc. The relative percentage of total
area that cells contracted was also highly variable. On some days, cells
contracted around 10% to 60% (Figure 9C). On other days, the cells showed
very little to no contraction when treated with ephrinA1-Fc. At this point, we
chose to stop pursuing this line of investigation.
Cloning of truncated EphA2
To test our hypothesis that TYPE7 could activate MMP cleaved EphA2 we
sought to generate stable cell lines expressing both full-length (as a control) and
N-terminal truncated EphA2. MT1-MMP is known to cleave EphA2 at 4 sites
(165). For our N-terminal truncation, we chose to recapitulate the S-423V
cleavage site. An EphA2-GFP expression vector was modified by site-directedmutagenesis to produce EphA2ΔN. Cell lines in which the WT EphA2-GFP and
the EphA2ΔN-GFP are stably expressed in HEK293 cells were produced.
HEK293 cells were chosen for their negligible endogenous EphA2 expression
(168). Imaging of GFP fluorescence in cells confirmed expression and
localization of both constructs (Figure 10A) while Western Blot analysis
confirmed the length of EphA2 produced by both cell lines (Figure 10B).
However, it appears that EphA2ΔN-GFP did not primarily get trafficked to the
plasma membrane. We saw significant cytoplasmic and ER levels of GFP. Total
EphA2 levels for both constructs show differences as can be seen in Figure 10B
with the WT construct having a larger band than the ΔN construct.
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Figure 9. Live cell contraction measurements.
A. Representative live PC-3 cells at low confluency imaged by phase contrast.
B. and C. Cell areas measured over time from live-cell videos taken after
stimulation with 0.5 µg/mL ephrinA1-Fc for 30 minutes on two different days.
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Figure 10. Expression of truncated and WT EphA2-GFP vectors.
A. Brightfield and epifluorescence images of Hek293 cells transfected with
EphA2-GFP and EphA2ΔN-GFP 48 hours after transfection. B. Western blot of
transfected Hek293 cells showing no expression of EphA2 in untransfected
cells (first lane), full-length EphA2-GFP (second lane), and the smaller
truncated EphA2ΔN-GFP (third lane). Expected molecular weights are indicated
at arrows. β-actin was blotted for as a loading control.
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2.5 Discussion
Here we investigated how TYPE7 interacts with EphA2 in cancer cells. We
showed via fluorescence microscopy and co-localization analysis that TYPE7
associates with EphA2 in cancer cells. Further, this association was increased
upon addition of ephrinA1. These results were supported by coimmunoprecipitation experiments which confirmed a direct interaction between
EphA2 and TYPE7. It was also seen in these experiments that ephrinA1
increased the amount of TYPE7 that co-precipitated with EphA2 (49). We
propose that the increase in co-localization relates to the formation of large
EphA2 signaling clusters which occurs upon stimulation with ephrinA1 (123,
169). If TYPE7 binds to one interface of the EphA2 TMD it is possible that as
another interface forms dimers that the peptide gets pulled into the signaling
clusters. Sequestration of the peptide in receptor clusters would disrupt any
equilibrium dissociation that would occur outside of clusters. This could explain
why less TYPE7 is co-localized with EphA2 under basal conditions.
We next sought to determine if TYPE7 could induce cell rounding and
contraction similar to ephrinA1. Although initial experiments with a small number
of cells indicated that TYPE7 promoted an intermediate level of contraction in
A375 cells, further high-throughput analysis in A375 and PC-3 demonstrated that
TYPE7 had no significant effect on cell contraction. We observed a large
heterogeneity in cell sizes which may have been due to differences in cell cycle
and the kinetics of individual cell responses to treatment. Conducting
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experiments in live-cell experiments were further complicated by experimental
artifacts. No robust effect on cell contraction was observed even though TYPE7
was shown to have a very robust effect on cell migration which are both expected
outcomes of EphA2 tyrosine phosphorylation (130). This may be due to the fact
that TYPE7 promotes the phosphorylation of only Y772.
As has been shown for FGFR, specific adaptor proteins bind to specific
phosphorylated residues or patterns of phosphorylated residues in ligandactivated RTKs (72, 73). It may be that phosphorylation of Y772 is sufficient to
recruit the adaptor proteins and down-stream signaling activators which are
responsible for reducing cell migration. This would mean that in order to promote
cell contraction to the same degree as ephrinA1, a different tyrosine or
combination of tyrosines must be phosphorylated.
We had hoped to further characterize the ability of TYPE7 to inhibit cell
migration by demonstrating that it could modulate the activity EphA2 cleaved by
MT1-MMP. Toward this goal, I successfully cloned and expressed an N-terminal
truncated EphA2-GFP construct. The site of truncation was chosen to mimic one
of the known MT1-MMP cleavage sites. However, imaging indicated issues with
trafficking of the truncated protein. It may be that the levels of expression for this
construct are too high for the protein to be correctly folded resulting in the altered
trafficking and degradation.
Alternatively, it is possible that removal of the predicted signal peptide
(residues 1-23) at the N-terminus of EphA2 greatly reduces the ability of the
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protein to be targeted to the plasma membrane. Although not every membrane
protein has a signal peptide, they are known to partition into lipid bilayers and
greatly enhance the efficiency of membrane insertion in addition to ensuring
correct membrane topology (170). It is possible through modifications to the
vector (to modulate expression levels) and EphA2 sequence (addition of the
signal peptide) we could render a construct which gets efficiently trafficked to the
plasma membrane.
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Chapter III.
PIP2 promotes conformation-specific dimerization of the EphA2
membrane region
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3.1 Abstract
The EphA2 receptor exhibits two activation states: anti-tumorigenic liganddependent activation, and pro-tumorigenic ligand-independent activation.
Evidence suggests that in these two states the transmembrane domain (TMD)
dimerizes via two distinct helical interfaces: the ligand-independent dimer
mediated by a heptad repeat motif and the ligand-dependent dimer mediated by
a glycine zipper. It has also been proposed that positively charged residues on
the intracellular juxtamembrane (JM) segment interact with negatively charged
phosphatidylinositol 4,5-bisphosphate (PIP2) lipids on the inner leaflet of the
plasma membrane. Here we investigate the coupling of the TMD and JM in
different lipid environments. We devised a method enabling us to study the two
putative signaling conformations of a peptide comprised of TMD and JM residues
of EphA2 by varying membrane thickness using 14:1 PC and 22:1 PC. We found
that bilayer thickness alters the environment of the JM residues but not distance
from the bilayer surface. In thick bilayers addition of PIP2 results in changes to
JM environment and headgroup distance which appears to be driven by PIP 2
clustering around the basic JM residues. No effect of PIP2 on the JM was
observed in thin bilayers. Using a novel single-molecule TIRF technique we
observed that in thick bilayers PIP2 promotes TMD dimerization. This effect on
self-assembly was not observed in thin bilayers or in thick bilayers containing
another negatively charged lipid, phosphatidylserine. These data suggest that
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PIP2 exerts a specific regulatory effect on EphA2 through interactions with the JM
in the ligand-independent state.
3.2 Introduction
The Eph receptor tyrosine kinases (RTKs) are the largest family of RTKs
in humans. Eph receptors are involved in tissue patterning during embryonic
development, neuronal plasticity, and wound healing (130, 171). Beyond their
normal physiological functions, Eph receptors can contribute to human diseases.
For example, elevated EphA4 signaling results in neuronal damage in
Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) (90, 98, 101, 102),
and loss of EphB2/B3 signaling is implicated in skeletal malformations that cause
cleft palate (172). Moreover, a large body of research exists establishing that Eph
receptors are overexpressed in a variety of cancer types. Specifically, EphA2
overexpression is found in breast, ovarian, prostate, and pancreatic cancers and
is correlated with aggressive tumors, high rates of tumor recurrence, and poor
patient prognosis (104–108, 110, 173). Additionally, Eph receptors have been
found to be cellular receptors for viruses that cause cancer. For example, EphA2
is a receptor for Kaposi’s sarcoma-associated herpes virus and Epstein-Barr
virus (114, 174).
EphA2 signaling pathways control cell proliferation, migration, and cell
retraction (119). EphA2 engages in two modes of signaling: ligand-dependent
and ligand-independent (i.e. non-canonical). Ligand-dependent signaling requires
activation of EphA2 by binding of its ligand, ephrinA1, resulting in the
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phosphorylation of residues Y588, Y594 and Y772. This results in signaling that
inhibits metastatic phenotypes by causing cell retraction/rounding and decreasing
cell proliferation and migration (124, 129, 130). Conversely, ligand-independent
signaling is responsible for tumorigenic phenotypes and occurs via
phosphorylation of S897 by the kinases AKT, RSK, or PKA (124–127).
Overexpression of EphA2 in cancers is often accompanied by a loss of ephrin
ligand (120, 121). It is believed that this imbalance of EphA2 and ephrin results in
both increased ligand-independent signaling and a decrease in ligand-dependent
signaling, promoting tumor growth and malignancy (175).
Due to its prominent role in tumorigenesis, EphA2 has become an
attractive drug target and, as such, an active area of research. The structure of
EphA2 includes an extracellular ligand binding domain, a single pass
transmembrane domain (TMD), and an intracellular kinase domain connected to
the TMD by a disordered juxtamembrane (JM) segment. In the ligandindependent state, EphA2 exists in a monomer-dimer equilibrium (176). Upon
binding of ephrinA1, dimerization via the ligand-binding domains is promoted and
leads to the formation of signaling clusters (56). While many aspects of Eph
receptor signaling have been elucidated, the exact molecular details of how the
receptor transmits an extracellular signal across the plasma membrane remain
unknown. As a membrane spanning receptor, the TMD must play a role in
conferring signals across the plasma membrane.
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An NMR structure of the EphA2 TMD dimer was solved by Bocharov et
al. (137). It was found that this dimer had a small interhelical crossing angle (15°)
and the interface was mediated by a heptad repeat (HR) motif. The same study
conducted molecular dynamics (MD) simulations on the NMR structure and
found that the EphA2 TMD dimer could rotate to a glycine zipper (GZ) interface
with a larger interhelical crossing angle (45°). It was then hypothesized that the
receptor switches between these two conformations with different dimerization
interfaces. In a follow-up study, it was reported that mutations in the HR motif
decreased ligand-independent signaling while mutations in the glycine zipper
decreased ligand-dependent signaling (22). These findings combined with the
structural data gave rise to the following model: In the ligand-independent
signaling state the EphA2 TMD dimerizes via the HR motif with nearly parallel
TMDs, while in the ligand-dependent signaling state, EphA2 dimerizes via the GZ
with tilted helices (22, 137). It is unknown how the switch in dimerization interface
and opening of the interhelical crossing angle participate in conferring the
extracellular signal from the outside of the cell to the cytoplasm. It is further
unknown how the JM responds to changes in the TMD.
JM-lipid interactions play a role during the activation of several receptors.
These interactions are believed to be mediated by positively charged JM
residues interacting with negatively charged lipid head groups. For EphA2,
associations between basic JM residues and phosphatidylinositol 4,5bisphosphate (PIP2) have been computationally predicted (159). Notably, the first
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five positively charged residues (HRRRK) of the EphA2 JM are predicted to have
strong interactions with the negatively charged PIP2. However, this association
has not been examined experimentally. The interaction of the JM with PIP2 might
regulate the activity of EphA2, since the two signaling modalities of EphA2 alter
PIP2 levels. Ligand-dependent signaling activates PI3K which phosphorylates
PIP2 to generate PIP3. While ligand-independent signaling recruits SHIP2 which
converts PIP3 to PIP2 and can be triggered by AKT upon PI3K activation (119).
However, it is unknown if these local changes in PIP2 directly alter EphA2
signaling.
In the present study, we investigate how the TMD and JM regions of
EphA2 are affected by signaling-related changes in TMD orientation and lipid
environment. We use hydrophobic matching to stabilize the two signaling
modalities of the EphA2 TMD region. We also examine how bilayer composition
affects the environment and position of JM residues. Our findings show that
bilayer thickness drives differences in the environment of the JM, while addition
of PIP2 alters the distance of the JM to the bilayer. We also examine how bilayer
composition affects self-assembly of the TMD of EphA2 using a novel single
molecule approach with styrene maleic acid lipid particles (SMALPs). Our results
indicate that PIP2 promotes dimerization only in thick bilayers via interactions with
the JM. Implications for the role of lipids in the two signaling states of EphA2 are
discussed.
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3.3 Methods
Liposome Preparation
Lipids were purchased from Avanti Polar Lipids, Alabaster, AL. 14:1 PC (1,2dimyristoleoyl-sn-glycero-3-phosphocholine), 22:1-PC (1,2-dierucoyl-sn-glycero3-phosphocholine), PIP2 (L-α-phosphatidylinositol-4,5-bisphosphate (Brain,
Porcine)), 18:1 dansyl-PE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(5dimethylamino-1-naphthalenesulfonyl), POPC (1-palmitoyl-2-oleoyl-glycero-3phosphocholine), biotin-PE (1-oleoyl-2-(12-biotinyl(aminododecanoyl))-snglycero-3-phosphoethanolamine), PIP2 Bodipy FL (Echelon Biosciences, Salt
Lake City, UT) stocks were prepared in chloroform. Aliquots of lipids were dried
under argon gas and then placed in a vacuum overnight. Unless otherwise noted
lipid films were resuspended with Buffer A: 19.3 mM HEPES (4-(2-hydroxyethyl)1-piperazineethanesulfonic acid) buffer (pH 7.5), 1 mM EGTA (ethylene glycolbis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid), and 5 mM DTT (dithiothreitol)
. Large unilamellar vesicles (LUVs) were formed by extrusion with a MiniExtruder (Avanti Polar Lipids, Alabaster, AL) through a 100 nm pore size
membrane (Whatman, United Kingdom).
Peptide Conjugation
The TMJM peptide was synthesized by F-moc chemistry by ThermoFisher
(Waltham, MA), and purity (>95%) was assessed by MALDI-TOF and HPLC. The
cysteine of TMJM was conjugated to Alexa Fluor 488 or Cyanine5, using a C5
maleimide moiety (Molecular Probes, Eugene OR). The reaction was carried out
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by adding a molar excess (peptide:dye of 1:1.1 moles) of dye dissolved in 100
mM sodium phosphate pH 7.6 to a peptide stock in 2,2,2-trifluoroethanol (TFE).
Unreacted dye was removed by HPLC by injecting the TFE mixture onto a semipreparative Agilent Zorbax 300 SB-C18 column on an Agilent 1200 HPLC system
(Santa Clara, CA). The gradient of water + 0.05% trifluoroacetic acid (TFA) to
acetonitrile + 0.05% TFA was 30 min from 0% - 100% acetonitrile. The
conjugated peptide eluted around 95% acetonitrile. The collected fractions from
HPLC were frozen and lyophilized. The dry conjugated peptide was resuspended
in hexafluoroisopropanol (HFIP).
Oriented Circular Dichroism
A stock of TMJM was prepared in TFE. Aliquots of 2.23 x 10-7 moles of 14:1 PC
or 22:1 PC were dried under argon then vacuum desiccated for at least 2 hours.
The appropriate amount peptide stock (for a 50:1 or 300:1 lipid to peptide molar
ratio) was added, dried with argon then dried under vacuum at least 2 hours. The
lipid-peptide film was resuspended with 400 µl TFE and 150 µl spread on each of
two circular quartz slides (Hellma Analytics, Germany). To allow for even solvent
evaporation, the slides were placed in a fume hood overnight and further dried
under vacuum for at least 6 hours to ensure complete evaporation of the TFE.
The samples were hydrated under argon with 150 µl per slide of Buffer A
overnight in 96% relative humidity, to obtain supported bilayers. Excess buffer
was removed, and the hydrated slides were assembled in an OCD cell, with an
inner cavity filled with saturated K2SO4 to keep the bilayers humidified. The OCD
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spectra were recorded on a Jasco J-815 spectropolarimeter at room
temperature. For each sample eight 45° rotations of the cell were averaged.
Appropriate lipid backgrounds were subtracted in all cases.
Tryptophan Fluorescence
13 mm glass culture tubes (Fisher Scientific) were cleaned with piranha (75%
H2SO4, 25% H2O2) solution for 3 minutes creating a hydrophilic surface to
promote efficient removal of peptide. Appropriate amounts of 100% 22:1 PC/14:1
PC or 3 mol% PIP2 and 97 mol% 22:1 PC/14:1 PC stocks were added to the
cleaned tubes and dried under argon. Next, the lipids were dried under vacuum
for at least 2 hours before the appropriate amount of peptide stock was added to
achieve a lipid to peptide molar ratio of 300:1 and subsequently dried under
vacuum overnight. Films were resuspended in Buffer A for an initial peptide
concentration of 4 µM and extruded. To maximize peptide recovery,
resuspension was conducted in three stages. First, 50% of the buffer volume was
added to the tube then vortexed for 45 sec. This buffer was removed then the
procedure was repeated twice with 25% of the final buffer volume. Equivalent
lipid blanks were also prepared. To ensure that amounts of lipids between blanks
and proteoliposomes were equal, ammonium molybdate phosphate assays were
performed to quantify lipids (177). If necessary, lipid blank concentrations were
appropriately adjusted. LUVs were then diluted to 300 µM lipid and 1 µM peptide
and 5 mM CaCl2 (where indicated). Samples were incubated for a minimum of 1
hour at room temperature to allow calcium levels to equilibrate across the bilayer.
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Tryptophan fluorescence spectra were then collected on a Cary Eclipse
Fluorescence Spectrophotometer (Agilent Scientific, Santa Clara, CA) using an
excitation wavelength of 290 nm. Lipid blanks were subtracted in all cases.
Trp-DNS FRET
Lipids and peptide were dried in piranha-cleaned glass tubes as described
above. Films were resuspended as described above in Buffer A for an initial
peptide concentration of 4 µM. Equivalent lipid blanks were also prepared.
Liposomes and proteoliposomes containing 0% and 10% dansyl-PE were mixed
in appropriate ratios and subjected to seven rounds of freeze thaw to achieve
0%, 0.25%, 0.5%, 1%, 2%, 3%, and 5% dansyl-PE, +/- 1 µM peptide, and +/- 5
mM CaCl2 final concentrations where indicated. Samples were incubated at room
temperature for a minimum of 1 hour to allow calcium levels to equilibrate. FRET
experiments were conducted on a Cary Eclipse Fluorescence Spectrophotometer
(Agilent Scientific, Santa Clara, CA) using an excitation wavelength of 290 nm.
Calcium Influx Assay
POPC vesicles were prepared by resuspending dried POPC with Buffer A, and
0.1 mM Indo-1 (1H-Indole-6-carboxylic acid, 2-[4-[bis-(carboxymethyl)amino]-3[2-[2-(bis-carboxymethyl)amino-5-methylphenoxy]ethoxy]phenyl]-,
pentapotassium salt). LUVs were formed via extrusion as described above. To
separate encapsulated Indo-1 and free Indo-1, LUVs were subjected to size
exclusion chromatography on a sephadex G25 PD-10 column (GE Life Sciences,
Chicago, Il). The concentration of the encapsulated Indo-1 was estimated using
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fluorescence and known amounts of free Indo-1. Indo-1 containing LUVs were
diluted to a final Indo-1 concentration of 0.05 µM in Buffer A and 5 mM CaCl2
was added. Calcium influx was observed in a Cytation5 plate reader (BioTek,
Winooski, VT) as a shift in fluorescence maximum from 485 nm to 405 nm.
Calcium influx saturated after 5 minutes. Free dye with 5 mM CaCl2 and
encapsulated dye with 0.1% Triton X-100 were used as controls.
SMALP preparation
For photobleaching experiments, peptide and lipid films were prepared by drying
down 22:1 PC or 14:1 PC + 3% biotin-PE ± 3% PIP2 or 10% POPS from
chloroform stocks. To this TMJM conjugated with Alexa 488 in HFIP was added.
For co-localization experiments, lipids and peptides were prepared the same way
as in photobleaching experiments with PIP2 Bodipy FL and TMJM conjugated to
Cy5. The amount of lipid was kept constant while the amount of peptide was
adjusted for the specified lipid to peptide ratio (300:1, 100:1 or 50:1). The films
were dried under argon gas, then vacuum-desiccated for at least two hours.
MLVs were then formed by resuspending in SMALP buffer (19.3 mM HEPES,
150 mM NaCl, 1 mM EGTA). MLVs were subjected to three rounds of freezethaw at -80 °C and 42 °C to ensure even mixing of the lipid components. A stock
solution of 1-9 mg/mL of SMA 2000H (Polyscope, Geleen, The Netherlands) was
diluted to 0.3 mg/mL and added to MLVs for a SMA final concentration of 0.075
mg/mL and lipid concentration of 100 µM. The MLV/SMA solution was then
incubated overnight with shaking to allow SMALP formation.
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Single molecule TIRF
Quartz microscope slides (G. Finkenbeiner Inc., Waltham MA) and coverslips
were cleaned following the protocol of Chandradoss et al. 2014 (178). Clean
slides and coverslips underwent animosalinization and pegylation following a
procedure previously described (179). In short, slides were incubated with a
solution of 93% methanol, 4.5% acetic acid and 2.5% 3-(triethoxysilyl)propylamine (EMD Millipore Corp., Billerica, MA), rinsed with methanol and water
and finally dried under a stream of nitrogen (179). A solution of m-PEG-SVA and
biotin-PEG-SVA (Laysan Bio Inc., Arab, AL) was made by dissolving 20% w/v mPEG and 1.25% biotin-PEG in filtered 100 mM NaHCO3 overnight. To assemble
a flow chamber, slides were pre-drilled with holes and fitted with a coverslip using
double sided tape and sealed with vacuum grease. Pegylated slides were
incubated for 10 min with 0.2 mg/mL streptavidin, and then washed with SMALP
buffer. SMALPs, containing a peptide concentration of 20-30 nM, were
immobilized on the slides for 10 min and then rinsed to remove any nonspecific
interactions. The rinse buffer was replaced with an oxygen scavenging system;
2.5 mM PCA and 250 nM rPCO (recombinant Protocatechuate 3,4-Dioxygenase;
Oriental Yeast Co., Tokyo Japan) in SMALP buffer with 2 mM Trolox (180).
Slides were imaged under a custom-based TIRF microscope and the emission
intensities were collected on CCD camera (Andor Technology) with 100 ms
integration time. A custom written software package (downloaded from
https://physics.illinois.edu/cplc/software) was used to record movies and extract
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single-molecule traces using scripts written in IDL (Harris Geospatial Solutions,
Inc) software (181). Single-molecule traces were assessed and analyzed using
custom software written in Python and analyzed to determine the number of
photobleaching steps. To prevent potential bias, the experimenter was blinded
during analysis with a custom data-shuffling Python script.
SDS-PAGE
Lipid-peptide films were prepared for SDS PAGE as described above with
unlabeled TMJM peptide at a lipid to peptide ratio of 300:1. Dried lipid-peptide
films were resuspended in 19.3 mM HEPES, 1 mM EGTA and shaken at room
temperature for 3 hours to allow disulfide bond formation. To the MLVs, SDS
buffer was added for a final SDS concentration of 150 mM. To this, sample buffer
+/- DTT was added. Samples were then boiled for 5-10 minutes to ensure
complete disruption of liposomes. To ensure the stock of peptide did not contain
disulfide-mediated dimers, a sample of the TMJM stock was also prepared
without lipid. This sample was resuspended in buffer containing 150 mM SDS
and loaded with sample buffer without DTT. Samples were run on a 16% tricine
gel and stained using a Peirce Silver Stain Kit (Thermo Scientific, Waltham MA).
Bands were quantified in ImageJ using the Band Peak Quantification plugin.
Transmission Electron Microscopy
SMALPs were prepared as described above to a final lipid concentration of 1
mM. 3% w/w SMA was used added to both lipids before overnight equilibration.
SMALPs of 14:1 PC were equilibrated with shaking at room temperature
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overnight while 22:1 PC SMALPs were incubated at 60 C for the same duration.
SMALPS were imaged with negative staining TEM. Small aliquots of SMALPs
were adsorbed on to glow discharged carbon-coated copper EM grids (Electron
Microscopy Sciences, Hatfield, PA) for 120 s. Grids were washed twice with
ddH2O for 15 s before negative staining with UranyLess (Electron Microscopy
Sciences, Hatfield, PA) for 45 s. Excess liquid was removed from the grid with
filter paper between steps. Grids were air-dried prior to examination on a JEOL
JEM 1400-Flash TEM (JEOL USA, Peabody, MA) operating at 80 kV. SMALPs
were measured in ImageJ.
Statistical Analysis
All statistical comparisons were made in IBM SPSS v25 software (Armonk, New
York USA). Where only two means were compared, student’s t-tests were used.
Where more than two means were compared one-way analysis of variance
(ANOVA) were conducted followed by post-hoc comparisons, with Tukey HSD
tests where data were homoscedastic, and Dunnett’s t-test where data were
heteroscedastic. All p-values reflect an α = 0.05. Where no p-values are shown
the difference is not significant.
3.4 Results
Bilayer thickness drives changes in TM orientation
We sought to generate an in vitro model of the ligand-independent and
ligand-dependent signaling states of the membrane region of the EphA2 (Figure
11A). To this end, we used the TMJM peptide, which comprises a short stretch of
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Figure 11. Bilayer thickness drives differences in TMJM helical tilt.
A. Sequence of the TMJM peptide comprised of EphA2 residues 531-563 with added
CWN residues at the C-terminus. B. OCD spectra of TMJM in 22:1 PC (fuchsia) and
14:1 PC (navy). Inset: model of the conformations of TMJM in 14:1 PC and 22:1 based
on OCD data.
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extracellular residues, the TMD and first 5 JM residues of EphA2. At the Cterminus we added a cysteine to enable dye conjugation, and a tryptophan as a
fluorescent reporter of the JM segment. As noted above, the two EphA2 signaling
configurations have different inter-helical crossing angles. To promote
the different configurations, we used model membranes composed of 14:1 PC or
22:1 PC, which only differ in the length of their acyl chains. Since 22:1 PC
contains 8 more tail carbons than 14:1 PC, it forms thicker bilayers (45.5 Å vs.
29.6Å) (182). Our hypothesis was that we could use hydrophobic matching to
stabilize the TMD of EphA2 in the two different conformations (183). Specifically,
TMJM would orient closer to the bilayer normal in a thick bilayer (22:1 PC), while
it would tilt further away from the bilayer normal in a thin (14:1 PC) bilayer. Thus,
we sought to use bilayer composition to tune helical tilt and recapitulate the
ligand-independent and ligand-dependent signaling configurations.
We used oriented circular dichroism (OCD) to test the effects of bilayer
thickness on the helical tilt of TMJM which had been reconstituted in supported
lipid bilayers composed of 14:1 PC or 22:1 PC. Fig. 1B shows that the obtained
OCD spectra had two α-helical minima indicating a transmembrane orientation.
To assess the helical tilt, we can examine the OCD spectra at the 208 nm
minimum. A more positive value indicates a less tilted helix, as seen in 22:1 PC,
while a lower value indicates a more tilted helix, as seen in 14:1 PC (Figure 11B)
(184–186). These data indicate that, on average, the TMDs are more vertical in
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thicker bilayers, like the ligand-independent signaling configuration. In contrast,
the TMDs are more tilted in thinner bilayers, which might correspond to the
ligand-dependent signaling state. The observed changes in tilt were independent
of lipid to peptide ratio and were also observed at lower peptide concentrations
(Figure 12B). Standard circular dichroism was performed on TMJM in 14:1 PC
and 22:1 PC vesicles to ensure that the secondary structure of the peptide was
the same in both lipids (Figure 12A). The OCD results suggest that the peptide
responds to being placed in bilayers of different thickness by adjusting the
interhelical crossing angle, providing a means to further study the two observed
conformations.
TMJM can form dimers in thin and thick bilayers
We wanted to investigate if TMJM self-assembled into biologically relevant
dimers. To this end we developed a single-molecule photobleaching method
using SMALPs. TMJM labeled with the fluorescent dye Alexa Fluor 488 was
reconstituted in multilamellar vesicles (MLVs) composed of either 14:1 PC or
22:1 PC containing traces of biotinylated phosphatidylethanolamine (biotin-PE).
The MLVs were then incubated with styrene maleic acid (SMA). SMA forms a
polymer belt around units of lipid bilayer and proteins (Figure 13A) (187, 188).
Transmission electron microscopy confirmed that lipid composition did not alter
SMALP size and co-localization experiments confirmed SMALP composition
(Figure 14 and Figure 15D-E). SMALPs were immobilized on a microscope slide
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Figure 12. CD and OCD TMJM controls.
A. CD of TMJM in 22:1 PC (fuchsia) and 14:1 PC (navy) liposomes at a lipid to
peptide ratio of 50:1 showing secondary structure in both lipids is α-helical. B.
OCD of TMJM in 14:1 PC (navy) and 22:1 PC (fuchsia) at a lipid to peptide ratio
of 300:1.
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Figure 13. TMJM dimerization observed by single-molecule TIRF of SMALPS.
A. Schematic of TIRF experimental setup. SMALP showing SMA polymer (yellow)
encircling lipids (blue) containing TMJM peptides (purple) labeled with Alexa488
(green), immobilized on a PEGylated slide via a biotin (black) and streptavidin
(orange) linkage. B. Representative fluorescence traces showing one (left) and
two (right) photobleaching steps. Representative TIRF image of SMALPs (inset).
C. Box and whiskers plot showing percentages of peptide counted in traces with
two photobleaching steps in 22:1 PC and 14:1 PC at a lipid to peptide ratio of
300:1. Data are from 3-6 independent experiments ± S.D, n is total number of
traces counted with two photobleaching steps.
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Figure 14. TEM of 14:1 PC and 22:1 PC SMALPS.
A. Representative TEM images of SMALPs comprised of 22:1 and 14:1 PC ± PIP2.
Scale bars in large images are 100 nm. Scale bars in insets are 25 nm. B.
Histograms of SMALP diameters. Top: 22:1 PC (solid bars) and 22:1 PC + PIP 2
(cross hatch). Bottom: 14:1 PC (solid bars) and 14:1 PC + PIP2 (cross hatch). Data
are from 3-4 independent SMALP preparations for each lipid composition. 80-100+
SMALPs were measured for each lipid composition.
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Figure 15. Controls for SMALP immobilization and composition.
A. Biotinylated slide with buffer only. B. A biotinylated slide without streptavidin
was incubated for 10 min. with SMALPs containing 3% biotin-PE and TMJM
Alexa488 and rinsed. Images show no immobilized SMALPs. C. A biotinylated
slide was incubated with 0.2 mg/mL streptavidin for 10 min followed by
incubation with SMALPs containing biotin-PE and TMJM Alexa488 then rinsed.
Image shows immobilized SMALPs. D. Co-localization of SMALPs with PIP2
Bodipy FL (left) and TMJM Cy5 (right) simultaneously excited. White arrows
highlight SMALPs containing both PIP2 and TMJM. E. Representative
fluorescent trace from co-localization shown in D showing TMJM Cy5 (red) with
two photobleaching steps and simultaneous fluorescence from PIP2 Bodipy FL
(green).
73

via a biotin-streptavidin linkage (Figure 13A, Figure 15A-C). Imaging was
conducted using total internal reflection fluorescence (TIRF) microscopy. By
analyzing the fluorescence of individual SMALPs over time, we can count
individual fluorophore photobleaching events (Figure 13B) to determine the
number of labeled TMJM peptides contained in a single SMALP. At a lipid to
peptide ratio of 300:1 we found a substantial fraction of the peptide in SMALPs
yielding two photobleaching steps Figure 13C). The majority of SMALPs
contained one or two labeled TMJM peptides. Only a small fraction of SMALPs
had 3 or more photobleaching steps (Figure 16). These results were robust as
similar values were found for 2 bleaching steps in 22:1 PC and 14:1 PC (Figure
13C). Similar percentages of SMALPs containing one and two peptides were
also observed at different lipid to peptide ratios (Figure 16). The single molecule
results suggest that TMJM is in a similar monomer-dimer equilibrium in 14:1 PC
and 22:1 PC.
Helical tilt alters environment of JM residues but not distance from the
bilayer surface
We next investigated if JM-lipid interactions are different in the two
conformations adopted by TMJM. We sought to understand if the change in
helical tilt observed for TMJM in thin and thick bilayers altered the position of the
JM residues. We used the tryptophan placed after the JM residues as a reporter
(Figure 11A) and fluorescence experiments were performed in 14:1 PC and 22:1
PC 100 nm vesicles. We observed that the fluorescence intensity of the
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Figure 16. Percentages of dimeric TMJM at different concentrations and
percentages of larger oligomers.
A. Percentage of dimeric peptide determined by SM-photobleaching at lipid to
peptide ratios of 100:1 and 50:1 in 22:1 PC SMALPs with and without PIP2.
Bars are averages of 3 independent experiments ± S.D B. Percentage of
dimeric peptide determined by SM-photobleaching at lipid to peptide ratios of
100:1 and 50:1 in 14:1 PC SMALPs with and without PIP2. Bars are averages of
3 independent experiments ± S.D C and D. Percentage of peptide in larger
oligomers in 22:1 PC and 14:1 PC SMALPs with and without 3% PIP2 and 5
mM Ca2+ via SM-photobleaching experiments. Data are from 3-6 independent
experiments. n = number of traces counted with 3 or more steps.
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tryptophan was higher in 14:1 PC than 22:1 PC (Figure 17A) but the spectral
maximum was similar (Figure 18). These data suggest a small change in the
environment of the tryptophan that is not related to differences in membrane
burial of the JM (189).
We next examined the association of the JM with the bilayer interface
using the tryptophan as a FRET donor and a headgroup-labeled dansyl
phosphatidylethanolamine (DNS-PE) as an acceptor. In both 14:1 PC and 22:1
PC in liposomes a decrease in donor fluorescence was observed upon the
addition of 0.25 - 3% acceptor, indicating that FRET occurred in all conditions
(Figure 19). By calculating the FRET efficiency (E) at 0.5% acceptor we were
able to quantify that the FRET occurring in 22:1 PC and 14:1 PC was similar
(Figure 17B). These data combined with the tryptophan fluorescence results
(Figure 17A) led us to conclude that interhelical crossing angle does not greatly
affect the association of the JM residues of TMJM with PC lipid bilayers.
PIP2 drives changes in JM-headgroup distance only in thick membranes
To begin examining the effects that anionic lipids have on the coupling of
TMD orientation and JM-lipid association, we repeated the OCD experiments in
the presence of 3% PIP2. We observed no large changes in helical tilt caused by
the addition of PIP2 in either thin or thick bilayers (Figure 20). Therefore, we
conclude that the addition of anionic lipids does not perturb the hydrophobic
matching driven changes in helical tilt observed in the original OCD experiments
(Figure 11B).
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Figure 17. Bilayer thickness and PIP2 alter Trp environment while
headgroup distance is changed by PIP2.
A. Normalized intensities of TMJM Trp in 22:1 PC and 14:1 PC liposomes in
the presence and absence of PIP2 and 5 mM Ca2+. p-values were determined
by Mann-Whitney U tests, bars are means ± S.D., n = 3 B. FRET efficiencies
calculated from FRET experiments with TMJM (Trp, donor) in 14:1 PC and 22:1
PC liposomes in the presence and absence of 3% PIP2 (3% DNS-PE, acceptor)
in liposomes (bars are means ± S.D., n = 3). (p-value is from one-way ANOVA
followed by Tukey post-hoc test).
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Figure 18. Tryptophan emission spectra and spectral maxima.
A. Trp emission spectra in 22:1 PC liposomes (solid fuchsia line), with 3% PIP2
(dashed line) and 3% PIP2 with Ca2+ (gray line) (curves are averages of 3
independent experiments). B. Trp emission spectra in 14:1 PC liposomes (solid
navy line), with 3% PIP2 (dashed line) and 3% PIP2 with Ca2+ (gray line).
Curves are averages of 3 independent experiments. C. Tryptophan
fluorescence spectral max in 14:1 PC and 22:1 PC liposomes with and without
3% PIP2. Bars are means ± S.D. from 3 independent experiments.
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Figure 19. Trp DNS-PE FRET emission spectra and efficiencies.
A. Representative emission spectra of Trp and Dansyl showing saturating
amounts of FRET at ~2% DNS-PE. B. FRET efficiencies of 1 µM TMJM in
LUVs with 0-3% DNS-PE without PIP2 or Ca2+ (purple), with 3% PIP2 (green),
and with 3% PIP2 and 5 mM Ca2+ (grey) in 14:1 PC liposomes. C. FRET
efficiencies of 1 µM TMJM in LUVs with 0-3% DNS-PE without PIP2 or Ca2+
(purple), with 3% PIP2 (green), and with 3% PIP2 and 5 mM Ca2+ (grey) in 22:1
PC liposomes. Points are averages of 3 independent experiments ± S.D.
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Figure 20. Helical tilt in thin and thick bilayers is preserved upon addition
of PIP2.
A. OCD spectra of TMJM in 22:1 PC with PIP2 (dashed line) and without PIP2
(solid line). Curves are averages of 3 independent experiments. B. OCD
spectra of TMJM in 14:1 PC with PIP2 (dashed line) and without PIP2 (solid
line). Curves are averages of 3 independent experiments.
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We next determined if PIP2 could cause changes in JM-membrane
interactions. We performed both tryptophan fluorescence and FRET
measurements. When examining tryptophan fluorescence, we added the divalent
cation Ca2+ as a control to shield the negative charges on PIP2. Saturating levels
of Ca2+ were used in these experiments as determined by calcium influx assays
(Figure 21). In 22:1 PC, we observed a statistically significant increase in
tryptophan fluorescence in the presence of PIP2 (Figure 17A). The observed
intensity increase was reversed upon the addition of Ca2+ (Figure 17A). This
reversal suggests that cationic JM residues are participating in an electrostatic
interaction with the anionic PIP2 headgroups, and that this interaction is placing
the JM tryptophan into a different position. However, there were no significant
fluorescence intensity changes in 14:1 PC in the presence of PIP 2, suggesting
that in a more tilted TM configuration, the JM residues are less sensitive to the
electrostatic interactions with PIP2 (Figure 17A). There were no significant
spectral maxima changes for either 14:1 PC or 22:1 PC upon addition of PIP 2
(Figure 18).
When we performed FRET experiments to determine the effect of PIP2 on
the JM region, we observed differences in FRET efficiency across a range of
acceptor concentrations, as expected (Figure 19). Figure 17B shows that in thick
bilayers the presence of PIP2 decreased FRET by roughly half. This indicates
that the distance between the JM tryptophan and the DNS-labeled lipid
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Figure 21. Peptide concentration and calcium influx controls.
A. Representative CD spectra of SDS washed tubes indicating comparable
levels of peptide were recovered for 22:1 PC (fuchsia) and 14:1 PC (navy)
liposomes in fluorescence experiments. B. (right) Blue shift of encapsulated
Indo-1 dye spectral maximum is observed after addition of 5 mM Ca2+. (left)
Calcium influx assays showing 5 mM Ca2+ crosses the membrane in
saturating amounts within 30 minutes.
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headgroups is increased by PIP2. This result agrees with the Trp fluorescence
intensity changes caused by PIP2 observed in thick bilayers (Figure 17A). By
contrast, in thin bilayers, PIP2 induced no significant changes in FRET efficiency
Figure 17B).
PIP2 drives increased oligomerization of TMJM only in thick membranes
Since changes in oligomerization accompany EphA2 signaling changes in
cells (176, 190), we next determined if the interactions observed between the JM
residues and PIP2 influenced oligomerization of the peptide. Specifically, we
used the single-molecule TIRF approach to examine the effect of PIP2 on the
self-assembly of TMJM, in thin and thick SMALPs. Transmission electron
microscopy was conducted, which showed that PIP2 did not alter SMALP size
(Figure 14). Figure 22A shows that PIP2 increased the amount of dimeric TMJM
peptide in 22:1 PC. The increased dimerization was reversed in the presence of
Ca2+, indicating that this effect is due to an electrostatic interaction between the
polybasic JM and the anionic PIP2 headgroup. While Ca2+ can destabilize
SMALPs, this effect is observed only at higher concentrations (>2 mM) than we
employed (191). In contrast, PIP2 did not affect dimerization in 14:1 PC (Figure
22B), nor do the counts for larger oligomers demonstrate a sensitivity to PIP 2
(Figure 16). Though they report on different aspects of the configuration of the
peptide, these data agree with the tryptophan fluorescence and FRET data,
which indicate that TMJM is sensitive to PIP2 only in thick bilayers. Our data
suggest that PIP2 has a specific effect, which is limited to the conformation of
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Figure 22. PIP2 promotes self-assembly of TMJM in thick bilayers
A and B. Percentage of TMJM-Alexa488 peptide in two-step photobleaching
traces in 22:1 PC and 14:1 SMALPs, respectively, determined by singlemolecule studies. The effect of the presence of 3% PIP2 and 1 mM Ca2+ are
investigated. Data are from 3-6 independent experiments. n is number traces
counted for each. p-values are from student’s t-tests with significance
determined after Benjamini-Hochberg procedure. C. Representative SDSPAGE (full gel can be seen in Figure 23) of unlabeled TMJM in 14:1 PC and
22:1 PC liposomes in the presence and absence of 3% PIP 2. Monomer and
disulfide-mediated dimers can be seen in non-reducing conditions. Addition of 5
mM DTT eliminates the disulfide-mediated dimer band. D. Quantification of 3
independent SDS-PAGE experiments as shown in C. Bands in each lane were
quantified in ImageJ and percent of dimer was calculated. Bars are means ±
S.D., p-value is from a student’s t-test. All data are from experiments at a lipid
to peptide ratio of 300:1, n = 3.
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Figure 23. Representative SDS-PAGE of TMJM crosslinking.
Representative SDS PAGE gel of TMJM crosslinking as shown in Fig. 4C.
Smears below 5 kDa are from lipids. Note: no smear is seen in first lane where
no lipid was added. Yellow discoloration in upper-right portion of gel is from
DTT.
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TMJM present in thick bilayers. Further, this effect is likely due to JM-PIP2
electrostatic interactions.
To further investigate the effects of JM interactions on the self-assembly of
TMJM we performed SDS-PAGE experiments where dimerization was
investigated by disulfide crosslinking. We reasoned that if PIP2-dependent
changes in self-assembly are promoted by lipid-JM interactions, this effect would
be observable as differences in band sizes on a protein gel. Instead of measuring
TMD-TMD interactions, as in the single-molecule experiments, we instead
examined JM-JM interactions. To do this, TMJM containing a free Cys residue at
the JM end was reconstituted in liposomes of 14:1 PC and 22:1 PC in the
presence and absence of 3% PIP2. The peptide stock remained monomeric in
our basal conditions (Figure 22C, first lane). In the absence of a reducing agent,
we observed two bands corresponding to monomer and disulfide-mediated dimer
in all lipid conditions (Figure 22C). The relative percentage of monomer and
dimer was measured for each lipid condition. We observed that in 22:1 PC + PIP2
vesicles, the percentage of disulfide-mediated dimer was higher than in 22:1 PC
alone (Figure 22D), in agreement with the single-molecule data in SMALPs. In
14:1 PC no effect of PIP2 was observed.
PS alters JM environment but not dimerization in thick membranes
Given the effects of PIP2 on TMJM, we wondered if phosphatidylserine
(PS), an anionic lipid abundant at the plasma membrane, would also exert similar
effects on the JM residues and dimerization of TMJM. The net charge of PS is -1,
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while PIP2 has on average a charge of -3 (192). To achieve a similar net charge
in our model membranes, we used 22:1 PC with 10% PS (compared with 3%
PIP2). This value is similar to PS levels found in the plasma membrane of
eukaryotic cells (193). We tested for changes in tryptophan fluorescence and
oligomerization in 22:1 PC, where PIP2-dependent changes were observed
previously. As with the tryptophan fluorescence experiments, a significant
increase in fluorescence intensity was observed in the presence of PS (Figure
24A). However, unlike the PIP2 experiments, this increase was not fully reversed
in the presence of saturating amounts of Ca2+, suggesting differences in the
effect of the two anionic lipids. Furthermore, single-molecule experiments
showed that the presence of PS did not promote dimerization (Figure 24B).
These data suggest that PS alters the environment of the JM residues like PIP2,
but without simultaneously driving significant changes in dimerization.
3.5 Discussion
We developed a reconstituted system that could stabilize the membrane
region of the EphA2 receptor in two different configurations. OCD experiments
performed in bilayers comprised of 14:1 PC indicated that the TMJM peptide
adopted a highly tilted TM arrangement, as revealed by the presence of two wellresolved spectral minima at 208 and 224 nm (184–186). On the other hand, OCD
results in the thicker 22:1 PC bilayers showed different features: the signal in the
200-230 nm range was less negative, and the 208 nm minimum was less
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Figure 24. PS interactions with TMJM in thick bilayers
A. Normalized fluorescence intensities from emission spectra of TMJM in 22:1
PC liposomes with 10% POPS and 5 mM Ca2+. Bars are means ± SD, n = 3. pvalues were determined by Mann-Whitney U tests. B. Percentages of dimeric
TMJM from SM-photobleaching experiments in 22:1 PC examining effects of
10% POPS and 1 mM Ca2+. Data are from 3-6 independent experiments. n is
number traces counted for each. No statistically significant differences were
found.
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pronounced, becoming a shoulder (Figure 11B). These differences clearly
indicate that in thick bilayers the TMJM α-helix aligns close to perpendicular to
the bilayer plane. It is theoretically possible to use OCD to calculate specific
helical tilt angles (49), but we could not accurately carry out this approximation
due to uncertainties in the homogeneities of the supported bilayers employed in
OCD. However, there is an intriguing qualitative agreement between our data
and the two TM conformations reported for EphA2 (22, 137). The liganddependent dimer crossed the membrane in a highly tilted state (45°), while the
ligand-independent dimer has a small crossing angle (15°) (Figure 11B). Based
on this similarity, we propose that the two conformations found in our data might
correspond to the membrane structure EphA2 adopts in the two different
activation states: in 22:1 PC dimerization would occur with almost parallel
helices, as expected for the ligand-independent dimer. In 14:1 PC a highcrossing angle dimer would correspond to the conformation induced after ligand
(e.g., ephrinA1) binding. Our data indicate that this can be accomplished using
thin and thick bilayers by taking advantage of the strong propensity of the TMD to
avoid hydrophobic mismatch (183).
To ensure that the TMJM engages in biologically relevant dimerization we
employed two complementary methods. After finding artifacts in FRET
experiments performed in liposomes, we resorted to develop a new single
molecule approach that uses SMALPs, which have been shown to maintain
native membrane structures (Figure 13) (187, 188). We also performed a
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crosslinking assay in liposomes of the same lipid composition as the SMALPs.
While this method does not measure dimerization per se, it is expected to report
on a related event, the proximity of the JM cysteines. With these limitations in
mind, it is likely that this method does not give an exact measurement of the
amount of dimer in equilibrium, but an adequate estimation to make comparisons
between different lipid environments. Not surprisingly the two methods yield
different levels of dimerization of TMJM. However, they agree in reporting
comparable levels of the dimer found in 14:1 PC and 22:1 PC environments
(compare Figure 13C to Figure 22C-D). We conclude from the dimerization and
OCD data that our thin and thick bilayer systems promote two different helical
orientations of TMJM and that in both cases the peptide can from a dimer.
The JM segment of EphA2 is functionally important, as it contains the
residues Y588 and Y594, which are phosphorylated by the kinase domain of
EphA2. This event triggers the release of the receptor from the inactive,
autoinhibited state (119). Hedger et al. examined the interaction of basic JM
residues of 58 RTKs with anionic lipid headgroups via MD studies (159). They
concluded that JM residues closest to the TM have significant contacts with PIP2.
Specifically, for EphA2, their simulations predicted that the HRRRK region of the
JM contributed the most to contacts with PIP2. Similar observations have been
made in simulations of the JM and kinase domain of EphA2 in PIP2 containing
bilayers (194). However, these JM-PIP2 interactions have never been
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experimentally demonstrated. Based on this observation we included the HRRRK
residues in the TMJM peptide.
Using the tryptophan near the C-terminus as a sensor we were able
assess the JM environment in different lipid environments. Typically, burial of a
tryptophan in a membrane results in a blue shift of the spectral maximin and a
concurrent increase in fluorescence intensity (189). The change in bilayer
thickness had a significant effect on the tryptophan fluorescence intensity but no
accompanying shift in spectral maximum was observed. This uncoupling of
intensity and spectral maximum could be due to adjacent residues that can
quench tryptophan fluorescence. Specifically, the neighboring cysteine residue is
known to engage in excited-state electron transfer with tryptophans (195).
Further, it has been shown that tryptophan fluorescence spectra are sensitive to
nearby charged residues (196). This led us to conclude that the local
environment of the tryptophan is different in thin and thick bilayers, not because
of changes in environmental polarity but more likely due to changes in relative
orientation or proximity to the neighboring residues. When PIP 2 was added in
thick bilayers, the tryptophan fluorescence increased significantly and was
reversed upon the addition of Ca2+. This observation indicates that an
electrostatic interaction occurs between the polybasic JM residues and the
anionic PIP2 headgroups. We did not observe fluorescence changes with PIP 2 in
thin bilayers, indicating that the peptide is not sensitive to the charged lipids in
this alternate conformation.
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Complementary FRET experiments revealed that PIP2 altered the distance
of JM residues to the DNS-PE headgroups. A significant decrease in FRET in the
presence of PIP2 was only observed in thick bilayers. To explain the increase in
Trp fluorescence intensity and the decrease in observed FRET in 22:1 PC
vesicles containing PIP2 we have developed two possible explanations (Figure
25). First, it is possible that in the presence of PIP2 the JM gets more buried into
the core of the membrane vertically with respect to the plane of the bilayer
moving the Trp away from the headgroups. Alternatively, PIP 2 may be clustering
around the JM residues as their charges interact, and this crowding pushes the
DNS-PE headgroups out away from the tryptophan laterally in the plane of the
bilayer.
In single molecule experiments, PIP2 bilayers promoted TMJM
dimerization in thick bilayers, presumably via changes in TMD-TMD interactions.
To assess self-assembly via JM-JM interactions we conducted disulfide
crosslinking experiments (Figure 22C). SDS PAGE again showed that in thick
bilayers PIP2 promoted self-assembly. These results agree with the singlemolecule SMALP data and suggest that the increased TMD-TMD dimerization is
facilitated by PIP2 through JM interactions. In thin bilayers, no PIP2 dependent
changes in disulfide-mediated dimerization was observed, also in agreement with
the single-molecule data.
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Figure 25. Model of TMJM in thin and thick bilayers.
(top) In the ligand-independent signaling configuration TMJM exists in a monomerdimer equilibrium in the absence of PIP2. Charge-charge repulsion of the JMs must
be overcome for dimerization. In the presence of PIP2 the JM-lipid association
changes by either clustering of PIP2 around the JM or burial of the JM. This shields
the positive charges promoting dimerization. (bottom) In the ligand-independent
signaling configuration TMJM exists as a monomer and dimer. Due to the tilt of the
TM, charge repulsion of the JMs is not as large as in the ligand-independent state.
Neither JM environment nor dimerization is altered by PIP2.
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Our data indicates that there is coupling between the TMD orientation and
JM association with the bilayer, resulting from JM repulsion. In thick bilayers the
TMD is less tilted, placing the JM close to each other in the dimer. The resulting
electrostatic repulsion prevents further dimerization. The presence of PIP 2
attenuates these repulsive interactions to promote self-assembly via the TMDs.
In thin bilayers the TMD adopts a more tilted orientation and in this configuration
the JM is not sensitive to the presence of PIP2, as the JM are too far away to
repel each other in the dimer.
Based on previous work (22, 137) and our data we propose a model
where the TMD and JM can be coupled. In the ligand-independent state EphA2
dimerization is facilitated by the heptad repeat motif resulting in a more upright
orientation. In this configuration, the JM residues are tightly associated with the
inner leaflet of the cell membrane via electrostatic interactions with PIP 2 (Figure
25, top). Without PIP2, EphA2 dimerization would be less favorable due to
charge-charge repulsion of the JMs. We propose that this is overcome by either
clustering of PIP2 around the JMs or burial of the JM due to PIP2 interactions that
shield the charged JMs from each other. In the ligand dependent states, the TMD
dimers would rotate to the glycine zipper dimerization interface and open to
create a larger interhelical crossing angle. With the larger interhelical crossing
angle of the glycine zipper dimer, charge-charge repulsion due to the JMs is
decreased and thus PIP2 does not promote dimerization. In this conformation,

94

PIP2 is no longer able to exert the same effects on the JM residues or
oligomerization of EphA2 (Figure 25).
Tryptophan fluorescence data with PS suggest that, as with PIP2,
electrostatic interactions are enough to alter the environment of the JM region.
However, unlike PIP2, the PS interaction is not fully reversed upon addition of
saturating amounts of Ca2+. This could be due to differences in binding sites and
stoichiometry of the two lipids with Ca2+ ions (197, 198). Interestingly, PS did not
promote dimerization as PIP2 did, and the tryptophan fluorescence changes were
larger. This leads us to conclude that JM interactions with PS do alter the
environment of the JM but without promoting dimerization. In this case, the
charge density of PS may not be large enough to overcome the charge-charge
repulsion caused by the JM polybasic stretch whereas the larger charge density
of PIP2 is. It has been reported that PS engages in contacts with RTK JM
residues to a lesser degree than PIP2, which may explain why in our experiments
we see an effect of PS on JM environments but not on oligomerization (159).
Our data suggest that PIP2 might play a direct role in modulating ligandindependent EphA2 signaling by stabilizing ligand-independent dimers and
holding the phosphorylatable JM tyrosine residues at the plasma membrane.
PIP2-JM interactions have been demonstrated experimentally for several
receptors including the epidermal growth factor receptor (EGFR), fibroblast
growth factor receptor (FGFG), and tropomyosin receptor kinase A (TrkA) (21,
160, 199, 200). It is believed that these electrostatic interactions serve to
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sequester phosphorylatable JM residues, rendering them inaccessible to the
kinase domain, prior to activation of the receptor (21, 201). It is likely that this
effect is paired with the kinase domains also binding with the membrane, which
has been shown via MD for EphA2, and experimentally for EGFR (201, 202).
PIP2 may thus play a role in modulating ligand-independent signaling
levels. One study proposed that the tumorigenic signaling that occurs in the
absence of ligand is caused primarily by monomeric EphA2 (176). By promoting
dimerization of the unliganded state, PIP2 could be reducing this signaling as
well. Dimerization via PIP2 in the unliganded state would be modulated by the
SAM domains which are known to inhibit oligomerization (203). We speculate
that when the ligand-independent dimer binds to an ephrin ligand, EphA2
undergoes rearrangements including rotation and opening of the TMD crossing
angle that accompanies the release of the JM residues from PIP 2. Dimerization
via the glycine zipper would then no longer be promoted by PIP 2 but by
interactions between other parts of the full-length protein which are known to
oligomerize such as the cysteine rich domains and the ligand binding domains
which are known to interact through two different interfaces upon ligand binding
(56, 190, 204). The glycine zipper TMD dimer may also be further stabilized by
interactions with other proteins which may contribute to formation of large
signaling clusters. For example, it is believed that interactions between SAM
domains and dimers of SHIP2 may form large linear arrays (205, 206).
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These findings provide new insights that suggest that PIP2 and maybe
other phosphorylated inositols could directly act on EphA2, causing Aktindependent modulation of the receptor. We are currently working to test the
hypothesis that the lipid environment specifically regulates full-length EphA2 in
cells.
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Chapter IV. The effect of pHLIP on lipid diffusion in supported
lipid bilayers
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4.1 Abstract
In order to design effective membrane targeting peptides, it is useful to
understand how these peptides interact with membrane lipids. Using pHLIP as a
model for pH-responsive membrane-targeting peptides, we sought to understand
the effects pHLIP may have on lipid dynamics. Prior data suggested that pHLIP
may have an effect on lipid viscosity and therefore lipid diffusion. Here we
developed a method of measure lipid diffusion via fluorescence recovery after
photobleaching. A method of making unilamellar supported lipid bilayers was
created and a partially automated data analysis pipeline was written using
Python and Mathematica coding languages to extract diffusion coefficients. We
applied this to investigating the effect of pHLIP on lipid diffusion at different pH
values. We found that pH had no effect on lipid diffusion alone while our data
suggest that pHLIP may have some effects on lipid diffusion.
4.2 Introduction
Lipids were once thought to be a passive support component of cell
membranes. More recently, through various studies, it has become clear that
lipids play an active role in regulating membrane and membrane protein
functions (207). Specifically, membrane proteins are directly affected by
membrane curvature and thickness (208, 209). Bilayer thickness is not static and
fluctuates around an average. Interestingly, this dynamic thickening and thinning
occurs at timescales to protein conformational dynamics (210, 211). It is
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interesting therefore to probe the interplay between and protein and membrane
dynamics.
The pH low insertion peptide (pHLIP) is a well characterized pH
responsive transmembrane peptide. It is being studied for clinical applications
since pHLIP is soluble in aqueous solution as a random coil (state I), readily
sticks to membranes at neutral pH (state II) and inserts at low pH as an α helix
(state III) (Figure 2) (29, 33). As described in detail in Chapter 1, these
characteristics make pHLIP appealing for use as a drug delivery vehicle or for
targeting cells in environments with lower than normal physiological pH, one
hallmark of the tumor environment (31).
To better enable the application of pHLIP, and other pH responsive
peptides, as a therapeutic, it is important to fully understand the interplay
between the dynamics of the peptide and its lipid environment. To better
understand the affects pHLIP has on lipid dynamics a variety of biophysical
approaches have been applied. Neutron spin echo experiments conducted by
our lab indicate changes in membrane thickness fluctuation dynamics upon the
addition of pHLIP at pH 8 and again at pH 4. At pH 8 (state II) thickness
fluctuations appear to happen at a higher rate than controls while the rate slows
compared to controls at pH 4 (state III) (data not shown). Recent studies have
explored thickness dynamics and membrane viscoelastic properties (212, 213).
To investigate potential changes in viscosity associated with the presence of
pHLIP in state II and state III, we wanted to use fluorescence recovery after
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photobleaching (FRAP) in supported lipid bilayers (SLBs) to measure lipid
diffusion.
FRAP is used to monitor the two-dimensional diffusion of a population of
fluorescently labeled molecules by bleaching a defined region (Figure 26B) then
monitoring as bleached molecules diffuse out of the region and unbleached
molecules diffuse into the bleached region (Figure 26C). Passive diffusion
replenishes the fluorescence intensity to the region which was bleached.
Fluorescence data from the bleached region can be used to measure the mean
squared displacement per unit time (µm2/sec, for example) of the labeled
molecule. The fraction of fluorescent molecules in the bleached region that are
mobile (mobile fraction) can also be determined. FRAP can be conducted with
fluorescently labeled proteins, lipid, and other molecules and most confocal
microscopes are equipped to perform this technique.
A simple way to extract quantified data from FRAP is to determine the
time it takes for half of the initial fluorescence to recover or recovery half-time
usually represented as τ1/2. This metric provides a simple means of comparing
rates of diffusion and is easily acquired from FRAP data. However, making
comparisons of τ1/2 is only appropriate for data collected using identical bleaching
parameters. τ1/2 is dependent on the bleaching radius, bleaching protocol and the
size and environment of the diffusing molecule. A more robust and measure is
the diffusion coefficient, D (214, 215). Early work by Axlerod et al., 1976 and
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Figure 26. Theoretical FRAP images and recovery curve.
A. A lipid bilayer containing fluorescently labeled lipids. (MDougM, Principle of
FRAP, 2008, commons.wikimedia.org/wiki/File:Frap_diagram.svg) B. A high
intensity laser is used to beach a selected ROI. C. Passive lipid diffusion
results in bleached lipids moving out of the ROI area unbleached lipids moving
into the ROI. D. Diffusion eventually restores uniform fluorescence to the
imaged area.
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Soumpasis, 1983 produced the first mathematical models for fitting FRAP data to
extract diffusion coefficients (214, 215). For example, the Soumpasis equation:
𝐷 = 0.224

(1)

𝑟𝑛2
𝜏1/2

Where D is the rate of diffusion, rn is the nominal radius of the bleached
spot, and τ1/2 is the half time of recovery. However, these early models assume
that bleaching is instantaneous, and no diffusion occurs during this process. Due
to the scanning times of confocal microscope diffusion does occur during
bleaching and must be accounted for to accurately calculate D. To account for
this, Kang et al. recently published their simplified FRAP equation for circularly
bleached regions from confocal microscopes:
𝐷𝐶𝑂𝑁𝐹𝑂𝐶𝐴𝐿 =

(2)

𝑟𝑒2 + 𝑟𝑛2
8𝜏1/2

Where re is the effective bleaching radius of the postbleach spot profile.
Here we establish a protocol for producing uniform SLBs with which to
conduct FRAP experiments via confocal microscopy. We apply a version on
equation 2 to calculate diffusion coefficients. We then use this method to
investigate if pHLIP in state II and state III effects the rate of lipid diffusion.
4.3 Methods
Glass Microscope Slide Cleaning:
A slide cleaning protocol adapted from Lin et al. was followed (216).
Quartz microscope slides were boiled in 1% Contrad detergent for 20 minutes.
Slides were then sonicated for 30 minutes in a hot water bath sonicator. Slides
103

were then briefly rinsed with MilliQ water to remove detergent. Slides were then
soaked in piranha solution (75% sulfuric acid, 25% hydrogen peroxide) for 3
minutes. Slides were then thoroughly rinsed with MilliQ water. Slides were dried
under a stream of argon gas.
Lipid Preparation and Vesicle Fusion
Lipid preparation and vesicle fusion protocols were adapted from published
protocols (216, 217). The correct volumes of lipid stocks for a final concentration
of 1.2 mg/mL in 400 ul (99% 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)
(Avanti Polar Lipids, Alabaster Al) + 1% (1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl)) (Avanti Polar Lipids,
Alabaster Al) (NBD-PE)), were dried under inert gas followed by desiccation for
2-16 hours. Lipids were then resuspended in 200 µl MilliQ water then extruded
15 times through a 100 nm pore size filter. Vesicles were then diluted 2-fold in 20
mM sodium phosphate pH 7.4 + 300 mM NaCl for a final concentration of 10 mM
sodium phosphate pH 7.4 + 150 mM NaCl. Final lipid concentration was 1.2
mg/mL
On a clean, dried slide, a 0.5 mm deep silicone isolator (Grace Bio-labs
#664504) was placed. To the well the extruded lipid was added then covered and
protected from light for 1 hour. Slide wells were then rinsed with 10 mM sodium
phosphate pH 7.4 + 150 mM NaCl buffer 6-10 times.
FRAP
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FRAP was performed on the SLB at neutral pH with a Leica SP8 laser
scanning confocal using a 40x/1.30 HC PL APO CS2 oil immersion objective
using an argon laser at 488 nm. The FRAP protocol was as follows with a scan
speed of 1800 lines per second and averaging two lines: 10 pre-bleach images
were taken using 0.5% laser power then a 4 µm2 ROI was bleached for two
frames (approximately 1.15 sec) at 100% laser power using the zoom-in function.
Recovery was observed for 130 frames (about 75 sec). A total of 8 FRAP series
were performed. pHLIP was then added to the SLB (150:1 lipid to peptide) in
fusion buffer and incubated for 1 hour at room temperature. The FRAP procedure
was repeated 8 times on the bilayer with pHLIP in neutral pH (state II). Finally,
the buffer containing pHLIP was removed and replaces with 10 mM sodium
acetate + 150 mM NaCl pH 4 to drive membrane insertion of pHLIP (state III).
FRAP was repeated as described above.
Analysis
Pre-bleach and post-bleach intensities for the bleaching ROI and a
background ROI were exported from LASX software. A python script (Appendix
A) was written to copy these intensities from two separate files for each movie (a
total of 48 files per experiment) into one excel file, set the time of bleaching to t =
0, and normalize the bleached ROI data to the background ROI data. This
normalization of recovery data was performed to correct for total photobleaching
observed while imaging.

105

The effective radii of photobleaching were determined by measuring
fluorescence intensity across the bleached field using ImageJ. The intensities
across this region were normalized to pre-bleached intensities across the same
region. This was done for averaged data for each of the three treatment groups
and fit to the following equation (Appendix C) to determine effective radius (re)
(218):
𝑥2

𝐹𝑝𝑜𝑠𝑡𝑏𝑙𝑒𝑎𝑐ℎ (𝑥) = 1 − 𝐾 exp (− 𝑟 2 )

(3)

𝑒

Where F is the postbleach intensity, K is the bleaching depth (max intensity – min
intensity across the bleached field) and x is the length of the line used to
measure intensity across the bleached field.
The recovery data were then read into a Wolfram Mathematica notebook
(Appendix B) and fit to the following equation modified from Kang et al., 2012:
𝐾

𝐹(𝑡) = 𝐹𝑖 {1 − 1+𝛾2+2𝑡⁄𝐷} 𝑀𝑓 + (1 − 𝑀𝑓 )𝐹0

(4)
Where 𝛾 =

𝑟𝑛
𝑟𝑒

, Fi is the prebleach intensity, F0 is the postbleach intensity, K is

the bleaching depth, Mf is the fraction of fluorescent molecules that are mobile,
and t is the postbleach time. From the fittings, diffusion coefficients, (D in
µm2/sec), and mobile fractions (Mf) were determined for each FRAP movie and
averaged across each treatment condition.
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4.4 Results
Establishing a FRAP protocol for determination of diffusion coefficients
We were motivated to use FRAP on SLBs to investigate the possible
effects of pHLIP on lipid diffusion. At the time, there was no working protocol in
our lab for conducting these experiments. I sought out to hone a method for
making supported lipid bilayers. We first attempted to make POPC SLBs on
piranha slides using a simple vesicle fusion method. These early attempts
resulted in patchy bilayers with many defects. This was determined by attempting
FRAP experiments in which the bilayers containing a fluorescently labeled lipid
would be photobleached but no recovery would occur and therefore no lipid
diffusion in or out of the bleached area.
After several iterations of slide cleaning protocols and changing lipid
composition, the method described above resulted in uniform SLBs which when
photobleached recovered as expected (Figure 27A). FRAP experiments were
carried out on a laser scanning confocal. Images of an area of bilayer were
accumulated and then a region of interest (ROI) was bleached followed by further
imaging until the fluorescence intensity of the bleached area recovered
completely. This process resulted in two separate video files (pre-bleach and
post-bleach) for each bleaching event. To plot and fit these data, the pre-bleach
and post-bleach intensity of the ROI needed to be exported from the proprietary
software format into .csv files then combined into a single plot. Further, to
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Figure 27. Representative FRAP images, re measurement, and recovery
curve fitting.
A. Representative stills from a FRAP movie showing the post-bleach ROI
recovering fluorescence over time B. Representative image showing difference
between rn and re (bottom left). Example of ROI used to track background
photobleaching also shown (top right). C. Representative fitting (red line)
obtained for determination of re from fluorescence measurements across the
bleached area (blue line). D. Representative recovery curve plotted in
Mathematica (Appendix IC) (left) and representative fitting (red line) (right) for
determining D.

108

compensate for global photobleaching due to imaging, a background ROI (Figure
27B, top right) needed to be measured and exported. The FRAP data must then
be normalized to the background at every time interval in the movie. This meant
for an experiment with several conditions and technical replicates, a large
number of files would need to be exported, compiled, and normalized. To
accomplish this in a reasonable time frame an automated program became
necessary. For this the python script found in Appendix A was written.
Finally, it was noticed that due to the rapid diffusion of lipids during
photobleaching, the effective radius of the bleached area is in fact larger than
what is input (Figure 27B, bottom left). This phenomenon, as well as a method to
calculate the effective bleaching radius, was described by Kang et al. To do this,
the intensity across the bleached region is measured and fit to equation 1. A
script (Appendix C) was written for importing the intensities across the bleached
region and fitting the data to equation 1 (Figure 27C).
Our goal was to determine diffusion coefficients using equation 2 from
Kang et al., 2012 (218) for SLBs with and without pHLIP at high and low pH. To
plot and fit data from multiple experiments simultaneously, the Mathematica
notebook found in Appendix B was written which imports data from the files
generated by the python script in Appendix A. A representative normalized FRAP
curve and a fit to equation 2 can be seen in Figure 27D.
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Lipid diffusion in the presence of pHLIP
With a valid FRAP protocol and practical data analysis pipeline in hand,
we could begin testing the effects of pHLIP on lipid diffusion. Control experiments
show that alteration in pH alone have no effect on diffusion (Figure 28). Together
with the day to day homogeneity of SLB mobility, any alterations seen in the
presence of pHLIP can be reasonably attributed to lipid-peptide interactions.
Lipids were observed to diffuse at 0.42 ± 0.16 µm2/sec at pH 7.4 while addition of
pHLIP at a lipid to peptide ratio of 150:1 raised the diffusion coefficient to 0.86 ±
0.7 µm2/sec at pH 7.4 and finally, dropping the pH to 4 resulted in a diffusion
coefficient of 1.4 ± 1.9 µm2/sec (Figure 28). While an upward trend is observed in
these data, the wide variance of the data leaves no reliable conclusion to be
drawn. The mobile fraction data of lipid only at pH 7.4 preliminarily indicates that
the SLBs were of uniform mobility for any given experiment. The mobile fraction
of the supported lipid bilayers shows a decrease upon addition of peptide and a
further decrease to pH 4. Between sample variation in lipid mobility is relatively
low and prior experiments indicate no significant change in mobile fraction or
diffusion coefficient (Figure 29) upon decrease of pH from 7.4 to 4 on lipid only
samples. This would indicate that the changes seen in the data presented here
are likely due to the incorporation of pHLIP. However, the variability in the
diffusion coefficients are too large to draw reliable conclusions.
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Figure 28. pH does not effect the rate of lipid diffusion.
Diffusion coefficients in 75% DOPC, 4% DOPS, 20% cholesterol, 1% NBD-PE
bilayers at neutral and acidic pH. Bars are means ± S.D, n = 2. Difference is
not significant via a student’s t-test.
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Figure 29. Effects of pHLIP on lipid diffusion.
A. Mobile fraction and B. diffusion coefficients of 99% DOPC, 1% NBD-PE lipid
bilayers without pHLIP, +0.05 µM pHLIP at neutral pH (state II) and +0.05 µM
pHLIP at acidic pH (state III). Bars are means ± S.D, n = 2. Differences are not
significant.
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4.5 Discussion
Here we have established a protocol for reliably producing supported lipid
bilayers for FRAP experiments. We also provide here a protocol of exporting
FRAP data from Leica image files (Appendix IA). We then wrote a data analysis
pipeline starting with a Python program (Appendix IB) for formatting the exported
data. These data can then be read into a Mathematica program (Appendix IC)
and fit to equation 4 to determine a diffusion coefficient and mobile fraction for
each FRAP recovery curve. We further provide a method for measuring the
effective radius of bleaching by fitting data to equation 3 using a Mathematica
program (Appendix ID). These programs are freely available for use and can be
applied to FRAP data from any lipid composition collected via confocal
microscopy.
We applied our FRAP method and data analysis pipeline to characterizing
lipid diffusion of DOPC bilayers with and without pHLIP. We found that pH alone
did not alter lipid diffusion. When pHLIP was added, shifts in D were observed
but the magnitude of these shifts was highly variable making any interpretation
impossible. It is possible that this is due to pHLIP-induced heterogeneities in the
SLBs. D for SLBs prior to the addition of pHLIP was consistent (Figure 29B, lipid
at pH 7.5). Only after adding pHLIP did the variability in the data increase. It is
possible that upon insertion, some of the pHLIP molecules are interacting with
the glass slide acting as anchors which could have a different effect on lipid
diffusion than pHLIP which is freely diffusing with the lipids. This hypothesis
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could be tested by performing FRAP experiments on tethered lipid bilayers on
glass slides. Tethered lipid bilayers employ PEGylated lipids to establish a
separation between the bilayer headgroups and the glass slide.
Experiments with pHLIP in tethered bilayers or any pH responsive peptide
in either SLBs or tethered bilayers can provide interesting information about how
these peptides impact the lipid environment which they target. Understanding the
interplay between pH responsive peptides and cell membranes will allow
researchers better understand the mechanisms by which these peptides function
and allow for the design more effective peptides.
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Appendix I Python and Mathematica Scripts
A. FRAP analysis step-by-step protocol
1. Create a file to contain the image exports, Python code and Mathematica
notebooks
2. Open Lif project in LASX
3. Select a video and open the second of the two series (the one that begins
with the first bleached image)
4. Click on the “Quantify” tab
5. Draw an ROI over the bleached area, resize to correct diameter. Copy that
ROI and move the copy to another region of the image for background
measurements
*make sure “Annotations” is not highlighted when you draw ROI
** when you open different images series these ROIs will remain in the
same X,Y positions
6. In “Tools” tab select “Stack Profile” under Tool and “All in One” under Sort
Charts by Channels and ROIs
7. With ROIs in place right click on intensity plot, select “Export” then “Excel”
a. For each pre bleached images series name the files PreData1,
PreData2…
b. For each post bleach image series name the files FrapData1,
FrapData2…
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*This naming convention is used by the Python code and must
correctly adhere to spelling and case
8. Using the command line, navigate to the directory containing the “FRAP
Data Excel” (Appendix B) python file
9. Open the file in your text editor (Suggested: Vim)
10. Under the import functions where the code generates the file path and file
name change the .xlsx files names to your choice (they must be the same),
save and exit to the command line
11. To run the python script type python scriptname.py in the command line
a. The code will process all of the exported files and save the new data
to a new file which you named in step 10
b. The program quits and exits when it finds no more files to process
and will print to the command line “File __not found! Exiting”
12. The new file should be in the correct directory and is now ready for
analysis in Mathematica notebook (Appendix C)
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B. Python script which compiles and correctly formats .csv files
exported from Leica FRAP images for import into Mathematica script
(B)
import
import
import
import

openpyxl
csv
numpy
os

# Writing new excel file with times, intensities, and normalized
intensities
filepath = os.getcwd()+"\FranFrapData.xlsx"
wb = openpyxl.Workbook()
dest_filename = 'FranFrapData.xlsx'
j = 0
while True:
j += 1
preFile = 'PreData' + str(j) + '.csv' #loop though
sequentially named PreData_ files
frapFile = 'FrapData' + str(j) + '.csv' #loop through
sequntially named FrapData_ files
if not os.path.isfile(preFile):
print('File ' + preFile + ' not found! Exiting') # break
loop when PreData_ file not found
break
if not os.path.isfile(frapFile):
print('File ' + frapFile + ' not found! Exiting') #break
loop when FrapDat_ not found
break
#Opening Exported CSVs and copying times and intensities
#initializing list variables to recieve values
preTimes = []
preIntensities = []
preBackground = []
frapTimes = []
frapIntensities = []
frapBackground = []
with open(preFile, newline='') as csvfile: #while each
PreData file is open
reader = csv.reader(csvfile, delimiter=',')
next(reader) #ignore first line
next(reader) #ignore sceond line
for row in reader:
time = float(row[0]) #floating point number needs to
be specified, otherwise string
intensity = float(row[1])
background = float(row[2])
preTimes.append(time)
preIntensities.append(intensity)
preBackground.append(background)
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with open(frapFile, newline ='') as csvfile: #while each
FrapData file is open
reader = csv.reader(csvfile, delimiter=',')
next(reader)
next(reader)
for row in reader:
time = float(row[0])
intensity = float(row[1])
background = float(row[2])
frapTimes.append(time)
frapIntensities.append(intensity)
frapBackground.append(background)
# Dividing bleached ROI by background ROI = Normalized
intensities
# converting each list to requisite array for numpy
frapInt = numpy.array(frapIntensities)
frapBack = numpy.array(frapBackground)
preInt = numpy.array(preIntensities)
preBack = numpy.array(preBackground)
preNorm = numpy.array(preBackground)
frapNorm = numpy.array(frapBackground)
NormList = []
PreNormList = []
#numpy.divide(dividend array, divisor array, output)
numpy.divide(frapInt,frapBack,frapNorm)
numpy.divide(preInt, preBack, preNorm)
NormList = numpy.array(frapNorm).tolist()
PreNormList = numpy.array(preNorm).tolist()
#wrting into consecutive sheets of new excel workbook
ws1 = wb.create_sheet("Frap" + str(j), j-1)
header = ['Time','Bleached ROI','Background
ROI','Normalized']
for i in range(1, len(header)+1):
ws1.cell(row=1,column=i).value=header[i-1] #Column
headings
#Column 1
for i in range(1,len(preTimes)+1):
ws1.cell(row=i+1,column=1).value=-preTimes[len(preTimes)i]-0.578 # pre-bleach times counting up to -0.578 starting from
last pretime value
for i in range(1,len(frapTimes)+1):
ws1.cell(row=i+len(preTimes)+1,column=1).value=frapTimes[i-1]
#copying over post bleach times after prebleach times
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#Column 2
for i in range(1,len(preIntensities)+1):
ws1.cell(row=i+1,column=2).value=preIntensities[i-1]
#pre-bleach intensities first
for i in range(1,len(frapIntensities)+1):
ws1.cell(row=i+len(preIntensities)+1,column=2).value=frapIntensit
ies[i-1] #post-bleach intesities after pre-bleach
#Column 3
for i in range(1,len(preBackground)+1):
ws1.cell(row=i+1,column=3).value=preBackground[i-1]
#background pre-bleach intensities
for i in range(1,len(frapBackground)+1):
ws1.cell(row=i+len(preBackground)+1,column=3).value=frapBackgroun
d[i-1] #background post-bleach vaules
#Column 4
for i in range(1,len(preNorm)+1):
ws1.cell(row=i+1,column=4).value=preNorm[i-1] #Normalized
pre-bleach intensities
for i in range(1,len(frapNorm)+1):
ws1.cell(row=i+len(preNorm)+1,column=4).value=frapNorm[i1] #Normalized post-bleach intensities
wb.save(filepath)
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C. Mathematica script that plots and fits FRAP data for diffusion
coefficients
Model
frap = Fi*(1.0 - kappa/(1.0 + gamma^2 + 8.0*t*d/re^2))*
Mf + (1.0 - Mf)*F0;
Import L only Data
SetDirectory[NotebookDirectory[]];
fnames = FileNames["*.xlsx"];
fnames // TableForm
FrapData =
Table[Map[{#[[1]], #[[2]]} &,
Import["L+PNoRinses030818.xlsx", {"Data", i, All, {1, 4}}]],
{i,
Range[1, 8, 1]}];
Table[ListLinePlot[FrapData[[i]], PlotStyle -> Black,
PlotRange -> All, FrameLabel -> {"Time, sec", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
x = Table[
ListLinePlot[FrapData[[i]][[13 ;;]], PlotStyle -> Black,
PlotRange -> All, FrameLabel -> {"Time, sec", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
Analyze Lipid only
kappaRule = {kappa -> (Fi - F0)/Fi*(1.0 + gamma^2)};
F = Take[FrapData[[1, 13 ;;, 2]]];
F0 = F[[1]];
Fi = 1.0;
gamma = rn/re;
rn = 2.0;
re = 5.8;
Mf0 = 0.0;
d0 = 2.0;
nlm = Table[
NonlinearModelFit[
FrapData[[i]][[13 ;;]], {frap /. kappaRule}, {{Mf, Mf0}, {d,
d0}},
t, MaxIterations -> 1000], {i, Length[FrapData]}];
fitdata =
Table[Show[x[[i]],
Plot[nlm[[i]][t], {t, -5, 140}, PlotStyle -> {Red, Thick}]],
{i,
Length[nlm]}]
fittable =
Table[nlm[[i]][{"ParameterConfidenceIntervalTable"}], {i,
Length[FrapData]}] // TableForm
dc = Table[
nlm[[i]]["ParameterTableEntries"][[2, 1]], {i, Length[nlm]}]
A1 = Table[
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nlm[[i]]["ParameterTableEntries"][[1, 1]], {i, Length[nlm]}]
residuals =
Table[ListPlot[
Transpose[{FrapData[[i]][[13 ;;, 1]],
nlm[[i]]["FitResiduals"]}],
PlotStyle -> {Black, Large}, PlotRange -> All,
FrameLabel -> {"Time, sec", "Residuals"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
Import Lipid + Peptide pH 7.4 Data
SetDirectory[NotebookDirectory[]];
fnames = FileNames["*.xlsx"];
fnames // TableForm
FrapData =
Table[Map[{#[[1]], #[[2]]} &,
Import["L+PNoRinses030818.xlsx", {"Data", i, All, {1, 4}}]],
{i,
Range[8, 16, 1]}];
Table[ListLinePlot[FrapData[[i]], PlotStyle -> Black,
PlotRange -> All, FrameLabel -> {"Time, sec", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
x = Table[
ListLinePlot[FrapData[[i]][[13 ;;]], PlotStyle -> Black,
PlotRange -> All, FrameLabel -> {"Time, sec", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
Analyze Lipid + Peptide pH 7.4
kappaRule = {kappa -> (Fi - F0)/Fi*(1.0 + gamma^2)};
F = Take[FrapData[[1, 13 ;;, 2]]];
F0 = F[[1]];
Fi = 1.0;
gamma = rn/re;
rn = 2.0;
re = 6.8;
Mf0 = 0.0;
d0 = 2.0;
nlm = Table[
NonlinearModelFit[
FrapData[[i]][[13 ;;]], {frap /. kappaRule}, {{Mf, Mf0}, {d,
d0}},
t, MaxIterations -> 1000], {i, Length[FrapData]}];
fitdata =
Table[Show[x[[i]],
Plot[nlm[[i]][t], {t, -5, 140}, PlotStyle -> {Red, Thick}]],
{i,
Length[nlm]}]
fittable =
Table[nlm[[i]][{"ParameterConfidenceIntervalTable"}], {i,
Length[FrapData]}] // TableForm
dc = Table[
nlm[[i]]["ParameterTableEntries"][[2, 1]], {i, Length[nlm]}]
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A1 = Table[
nlm[[i]]["ParameterTableEntries"][[1, 1]], {i, Length[nlm]}]
residuals =
Table[ListPlot[
Transpose[{FrapData[[i]][[13 ;;, 1]],
nlm[[i]]["FitResiduals"]}],
PlotStyle -> {Black, Large}, PlotRange -> All,
FrameLabel -> {"Time, sec", "Residuals"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
Import L+P 4 Data
SetDirectory[NotebookDirectory[]];
fnames = FileNames["*.xlsx"];
fnames // TableForm
FrapData =
Table[Map[{#[[1]], #[[2]]} &,
Import["L+PNoRinses030818.xlsx", {"Data", i, All, {1, 4}}]],
{i,
Range[17, 24, 1]}];
Table[ListLinePlot[FrapData[[i]], PlotStyle -> Black,
PlotRange -> All, FrameLabel -> {"Time, sec", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
x = Table[
ListLinePlot[FrapData[[i]][[13 ;;]], PlotStyle -> Black,
PlotRange -> All, FrameLabel -> {"Time, sec", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
Analyze L+P 4
kappaRule = {kappa -> (Fi - F0)/Fi*(1.0 + gamma^2)};
F = Take[FrapData[[1, 13 ;;, 2]]];
F0 = F[[1]];
Fi = 1.0;
gamma = rn/re;
rn = 2.0;
re = 10.752715075200687;
Mf0 = 0.0;
d0 = 2.0;
nlm = Table[
NonlinearModelFit[
FrapData[[i]][[13 ;;]], {frap /. kappaRule}, {{Mf, Mf0}, {d,
d0}},
t, MaxIterations -> 1000], {i, Length[FrapData]}];
fitdata =
Table[Show[x[[i]],
Plot[nlm[[i]][t], {t, -5, 140}, PlotStyle -> {Red, Thick}]],
{i,
Length[nlm]}]
fittable =
Table[nlm[[i]][{"ParameterConfidenceIntervalTable"}], {i,
Length[FrapData]}] // TableForm
dc = Table[
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nlm[[i]]["ParameterTableEntries"][[2, 1]], {i, Length[nlm]}]
A1 = Table[
nlm[[i]]["ParameterTableEntries"][[1, 1]], {i, Length[nlm]}]
residuals =
Table[ListPlot[
Transpose[{FrapData[[i]][[13 ;;, 1]],
nlm[[i]]["FitResiduals"]}],
PlotStyle -> {Black, Large}, PlotRange -> All,
FrameLabel -> {"Time, sec", "Residuals"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[FrapData]}]
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D. Mathematica script to calculate effective bleaching radius from data
exported from FRAP images
Model
f = 1 - K * Exp[-x^2 / re^2];
Import and Fit Data
SetDirectory[NotebookDirectory[]];
fnames = FileNames["*.xlsx"];
fnames // TableForm
Data = Table[
Map[{#[[1]], #[[2]]} &,
Import["ReInputL+P7.4.xlsx", {"Data", i, All, {1, 2}}]], {i,
Range[1, 1, 1]}];
Table[ListLinePlot[Data[[i]], PlotStyle -> Black, PlotRange ->
All,
FrameLabel -> {"Microns", "Intensity"},
Frame -> {{Automatic, None}, {Automatic, None}}], {i,
Length[Data]}]
F = Take[Data[[1, 2 ;;, 2]]];
K0 = Max[F] - Min[F];
re0 = 6;
nlm = Table[
NonlinearModelFit[Data[[i]][[2 ;;]], {f}, {{re, re0}, {K,
K0}}, x,
MaxIterations -> 1000], {i, Length[Data]}];
fitdata =
Show[ListLinePlot[Data[[1]]],
Plot[nlm[[1]][x], {x, -10, 12}, PlotStyle -> {Red, Thick}]]
fittable =
Table[nlm[[i]][{"ParameterConfidenceIntervalTable"}], {i,
Length[Data]}] // TableForm
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Chapter IV. Conclusion
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5.1 Conclusions
In Chapter II we explored the association of a novel EphA2-targeting
peptide with EphA2 and its effects of cell morphology. We demonstrated via colocalization analysis and co-immunoprecipitation that TYPE7 interacts directly
with EphA2 in A375 cancer cells. Ligand-dependent activation of EphA2 results
in cell contraction and decreased cell migration and proliferation. While it was
found that TYPE7 treatment reduces cancer cell migration, we did not find that it
significantly resulted in cell contraction. This could indicate that the tyrosine,
Y772, which TYPE7 phosphorylates is not sufficient to induce downstream
signaling that results in cell contraction.
While we were able to show that TYPE7 has a specific effect on EphA2
signaling we do not understand the mechanism by which it acts. In order to better
understand TYPE7 and to design more effective TMD targeting peptides, we
need a better understanding of this region of EphA2. Thus, we sought, in Chapter
III, to investigate how the TM and JM of EphA2 contribute to changes in
signaling.
We used bilayer thickness and hydrophobic matching to recapitulate the
two TMD configurations of our TMJM peptide which correspond to ligandindependent and ligand-dependent signaling. We proposed that thick bilayers
promote the ligand-independent state while thin bilayers promote the liganddependent state. With this system we investigated changes in the JM and
oligomerization. Using tryptophan fluorescence, we found that bilayer thickness
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did result in changes in the local environment of the JM but not due to its
distance from the bilayer interface changing. We then also showed that TMJM
engages in biologically relevant dimerization using a novel single-molecule TIRF
technique.
Next, we investigated if the polybasic residues of the JM participate in
electrostatic interactions with the anionic lipid PIP2. Tryptophan fluorescence
experiments showed that, in thick bilayers, the environment of the tryptophan
changes with PIP2 and that this change is reversible upon addition of calcium. No
changes occurred in thin bilayers. FRET experiments showed that the distance
between the tryptophan and a fluorescently labeled lipid headgroup changed only
in thick bilayers with PIP2. Again, no PIP2-dependent changes were observed in
thin bilayers. Fluorescence and FRET data indicate that the JM is sensitive to
interactions with PIP2 only in the ligand-independent conformation. Finally, we
found that PIP2 promotes dimerization of TMJM in thick bilayers, again
corresponding to the ligand-independent state. These data informed our
proposed model in which PIP2 regulates EphA2 by stabilizing ligand-independent
dimers via electrostatic interactions with the JM. We found that this interaction is
specific to PIP2 as PS was unable to effect the same changes in the JM or
dimerization. This work demonstrated, for the first time, that there is, in EphA2, a
coupling of TMD orientation and JM-lipid associations which is at least specific to
phosphatidylinositol lipids.
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The results from Chapter III highlight how important protein-lipid
interactions are to the function of membrane proteins. To better understand how
lipids and TMDs interact with each other, in Chapter IV, we developed a FRAP
protocol and automated data analysis pipeline for experiments conducted on
supported lipid bilayers using confocal microscopy. The resulting protocol was
robust and valid as it reproduced known diffusion coefficients for SLBs. Further,
the Mathematica and Python programs presented in Chapter IV allow for
accurate and fast determination of diffusion coefficients from Leica image files.
We used pHLIP as a model TMD for to determine if it has an effect on lipid
diffusion. We were able to measure lipid diffusion before and after the addition of
pHLIP in the same bilayer. While this did not result in a statistically significant
difference in D, it did cause changes in the variability of D (i.e the standard
deviation of D after addition of pHLIP was much larger). Because experiments
were conducted on the same bilayer these changes must be due to the presence
of pHLIP. Changes to the experimental setup, such as using tethered bilayers
instead of supported bilayers, may lead to improvements which allow for
difference in the mean value of D to be detectable with pHLIP.
In summary, I have investigated transmembrane-lipid interactions of
EphA2 and pH responsive peptides using cell biology together with classical and
novel biophysical approaches. These projects have contributed to the
understanding of how pH responsive peptides interact with lipids and their protein
targets. We also characterized activation state-dependent TM-JM lipid
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interactions in EphA2 which both advances the understanding of this
developmentally important RTK and can aid designing targeted therapies.
5.2 Future Directions
We have shown that TYPE7 directly interacts with EphA2 in cancer cells.
This interaction has been shown to change levels of tyrosine phosphorylation
and inhibit cell migration. However, the mechanism by which TYPE7 exerts these
effects is not known. We have speculated that by forming a dimer with the EphA2
TMD, TYPE7 may occlude the ligand-independent specific interface and thereby
promote the ligand-dependent configuration. We have also speculated that
interactions of the poly-glutamic acid stretch of TYPE7 may interact with the
polybasic JM of EphA2 and alter its activation state. Based on the findings
described in Chapter III, experiments with TYPE7 and TMJM in thin and thick
bilayers may provide insights into the mechanism of TYPE7.
We have demonstrated that in thick bilayers (which corresponds to the
ligand-independent configuration) TMD and JM are sensitive to interactions with
PIP2. This interaction drives changes in JM and environment and promotes TMD
dimerization. If TYPE7 does in fact interact preferentially with the EphA2 ligandindependent interface this could be detected by repeating experiments detailed in
Chapter III with TYPE7. I would expect to find that TYPE7 decreases
dimerization of TMJM in single-molecule TIRF experiments in SMALPs
comprised of 22:1 PC.
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We further hypothesized that the poly-glutamic acid stretch at the Cterminus of TYPE7 interacts with the polybasic JM residues of TMJM. If this
interaction occurs it could be detectable via tryptophan experiments. We know
that interactions with PIP2 alter the environment of the TMJM tryptophan
(Chapter III) so if the addition of TYPE7 also alters the tryptophan environment it
would be detectable these experiments. First, I propose that fluorescence studies
be conducted in 22:1 PC liposomes containing TMJM as described with and
without TYPE7 to see if TYPE7 alters the JM alone. Then, the experiments could
be repeated in liposomes with 22:1 PC and PIP2. If electrostatic interactions
between TMJM and TYPE7 outcompete the interactions with PIP 2, I would
expect to see a different outcome from this experiment. It may be that TYPE7
reverses the PIP2 induced fluorescent changes or changes the fluorescence in a
different way. These experiments would be complimented with tryptophan-dansyl
PE FRET experiments to obtain quantitative information about changes in
distance of the TMJM tryptophan and bilayer headgroups.
In Chapter III, we propose that the juxtamembrane region of EphA2
interacts with PIP2 in a manner that involves PIP2 clustering around the polybasic
JM residues and/or causes the insertion of the JM into the core of the bilayer.
These two hypotheses could be supported or rejected by employing different
experiments. To investigate clustering of PIP2 around the TMJM peptide, we
have begun a collaboration with the lab of Adam Smith at the University of Akron.
They employ fluorescence correlation spectroscopy (FCS) to measure the rate of
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diffusion of lipids. If lipids cluster, they diffuse more slowly. They will conduct
FCS on SLBs containing fluorescently labeled PIP2 to measure a rate of
diffusion. Then they will add TMJM to detect if it slows down the rate of diffusion
thereby confirming or rejecting the cluster hypothesis.
In addition, the burial of the tryptophan of TMJM can be assessed via
various quenching experiments. Quenchers, like acrylamide, can be added to
liposomes containing TMJM to determine how solvated the JM is. If the
tryptophan is not buried in the membrane a higher amount of quenching would
be expected. To compliment this approach, spin-labeled phospholipids which
quench fluorescence can be employed. The spin label can be added at different
positions of the lipid acyl chain at various depths in the membrane. If the
tryptophan of TMJM is buried in the presence of PIP2, this experiment would
show higher levels of quenching.
We saw in Chapter III that in thick membranes, PIP2 promotes selfassembly of TMJM. To study the effects of PIP2 on the oligomerization of fulllength EphA2 in cells, we have proposed FCS experiments. Again, our
collaborators in the Smith lab will perform these experiments. They will use cells
which express a full-length EphA2 labeled with GFP. There are several drugs
which can alter the levels of PIP2 at the plasma membrane which can be added
to cells. Using FCS they will assess a baseline diffusion of EphA2. When cells
are treated with drugs which deplete PIP2, we would expect based on our data,
to see a decrease in dimerized EphA2 and therefore increase the rate of
131

diffusion. Conversely, we expect drugs which increase the levels of PIP2 to
promote more dimerization of EphA2 and decrease the rate of diffusion.
Our oligomerization data in Chapter III suggests another possibility about
EphA2 in cells. With PIP2, the ligand-independent conformation is more dimeric
than the ligand-dependent configuration. It is possible, that in cells, the HR dimer
is more energetically favorable than the GZ dimer keeping receptor in ligandindependent state until ligand activation and other parts of the protein from TMDs
to glycine zipper. To test this hypothesis in thin and thick bilayers we would need
to determine which dimer interface is utilized in each. This could be achieved by
changing different TM residues to cysteines and conducting cross-linking studies
to identify the dimer interface in each lipid. We could then use the singlemolecule TIRF experiments in SMALPs to determine dissociation constants in
thin and thick bilayers with PIP2. These additional studies on the TMD of EphA2
are the next steps toward characterizing the role of PIP2 plays in modulating
activity of the receptor in cells.
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